<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JOP</journal-id>
<journal-id journal-id-type="hwp">spjop</journal-id>
<journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id>
<journal-title>Journal of Psychopharmacology</journal-title>
<issn pub-type="ppub">0269-8811</issn>
<issn pub-type="epub">1461-7285</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0269881112450785</article-id>
<article-id pub-id-type="publisher-id">10.1177_0269881112450785</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Chronic treatment with selective I<sub>2</sub>-imidazoline receptor ligands decreases the content of pro-apoptotic markers in rat brain</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Garau</surname><given-names>Celia</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Miralles</surname><given-names>Antonio</given-names></name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>García-Sevilla</surname><given-names>Jesús A</given-names></name>
</contrib>
<aff id="aff1-0269881112450785">Laboratori de Neurofarmacologia, Institut Universitari d’Investigació en Ciències de la Salut (IUNICS), Universitat de les Illes Balears, Palma de Mallorca, and Redes Temáticas de Investigación Cooperativa en Salud-Red de Trastornos Adictivos (RETICS-RTA), Spain</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0269881112450785">Jesús A García-Sevilla, Laboratory of Neuropharmacology, IUNICS, University of the Balearic Islands, Cra. Valldemossa km 7.5, E-07122 Palma de Mallorca, Spain. Email: <email>jesus.garcia-sevilla@uib.es</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2013</year>
</pub-date>
<volume>27</volume>
<issue>2</issue>
<fpage>123</fpage>
<lpage>134</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">British Association for Psychopharmacology</copyright-holder>
</permissions>
<abstract>
<p>Selective I<sub>2</sub>-imidazoline receptor ligands induce neuroprotection through various molecular mechanisms including blockade of N-methyl-D-aspartate (NMDA) receptors. To investigate new neuroprotective mechanisms associated with I<sub>2</sub>-imidazoline receptors, the effects of selective (2-styryl-2-imidazoline (LSL 61122), 2-(2-benzofuranyl)-2-imidazoline (2-BFI), 2-(4,5-dihydroimidazol-2-yl) quinoline hydrochloride (BU-224)) and non-selective (idazoxan) I<sub>2</sub>-drugs on canonical apoptotic pathways were assessed in rat brain cortex. The acute treatment with LSL 61122 (10 mg/kg) reduced the content of mitochondrial (pro-apoptotic) Bax (-33%) and cytochrome c (-31%), which was prevented by idazoxan, an I<sub>2</sub>-receptor antagonist. The sustained stimulation of I<sub>2</sub>-imidazoline receptors with selective drugs (10 mg/kg, every 12 h for seven days) was associated with down-regulation of key components of the extrinsic (Fas receptor: -20%; Fas associated protein with death domain (FADD) adaptor: -47–54%) and/or intrinsic (Bax: -20–23%; cytochrome c: -22–28%) apoptotic signalling and/or up-regulation of survival anti-apoptotic factors (p-Ser194 FADD/FADD ratio: +1.6-2.5-fold; and/or Bcl-2/Bax ratio: +1.5-fold), which in the long-term could dampen cell death in the brain. Similar chronic treatments with LSL 60101 (the imidazole analogue of 2-BFI) and idazoxan (a mixed I<sub>2</sub>/α<sub>2</sub>-ligand) did not induce significant alterations of pro- or anti-apoptotic proteins. The disclosed anti-apoptotic mechanisms of selective I<sub>2</sub>-imidazoline drugs may work in concert with other molecular mechanisms of neuroprotection (e.g. blockade of NMDA receptors) that are engaged by I<sub>2</sub>-ligands.</p>
</abstract>
<kwd-group>
<kwd>Apoptotic signalling</kwd>
<kwd>2-BFI</kwd>
<kwd>BU-224</kwd>
<kwd>FADD adaptor</kwd>
<kwd>Fas receptor</kwd>
<kwd>I<sub>2</sub>-imidazoline receptor</kwd>
<kwd>LSL 61112</kwd>
<kwd>mitochondrial proteins (Bcl-2, Bax, cytochrome c)</kwd>
<kwd>neuroprotection</kwd>
<kwd>rat brain</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0269881112450785" sec-type="intro">
<title>Introduction</title>
<p>During the past decades the pharmacological characterisation of imidazoline binding sites, recognized by imidazol(ine)-guanidine compounds, has defined a novel family of putative receptors comprising the I<sub>1</sub>-, I<sub>2</sub>- and I<sub>3</sub>-types for which agmatine is an endogenous ligand (<xref ref-type="bibr" rid="bibr66-0269881112450785">Regunathan and Reis, 1996</xref>; <xref ref-type="bibr" rid="bibr16-0269881112450785">Eglen et al., 1998</xref>; <xref ref-type="bibr" rid="bibr52-0269881112450785">Morgan and Chan, 2001</xref>; <xref ref-type="bibr" rid="bibr76-0269881112450785">Uzbay, 2012</xref>). Intensive research has been devoted to the biochemical and structural characterisation of imidazoline-binding proteins (<xref ref-type="bibr" rid="bibr17-0269881112450785">Escribá et al., 1995</xref>, <xref ref-type="bibr" rid="bibr18-0269881112450785">1999</xref>; <xref ref-type="bibr" rid="bibr62-0269881112450785">Raddatz et al., 1995</xref>, <xref ref-type="bibr" rid="bibr63-0269881112450785">1997</xref>; <xref ref-type="bibr" rid="bibr60-0269881112450785">Piletz et al., 2000</xref>; <xref ref-type="bibr" rid="bibr51-0269881112450785">Molderings et al., 2007</xref>; <xref ref-type="bibr" rid="bibr39-0269881112450785">Kimura et al., 2009</xref>) and their second-messenger systems (<xref ref-type="bibr" rid="bibr70-0269881112450785">Separovic et al., 1996</xref>; <xref ref-type="bibr" rid="bibr31-0269881112450785">Greney et al., 2000</xref>; <xref ref-type="bibr" rid="bibr15-0269881112450785">Edwards et al., 2001</xref>; <xref ref-type="bibr" rid="bibr46-0269881112450785">Lui et al., 2010</xref>), but much remains to be elucidated. Nonetheless, agmatine and imidazoline receptor ligands induce several biological activities with great therapeutic potential (<xref ref-type="bibr" rid="bibr34-0269881112450785">Head and Mayorov, 2006</xref>; <xref ref-type="bibr" rid="bibr71-0269881112450785">Smith et al., 2009</xref>; <xref ref-type="bibr" rid="bibr42-0269881112450785">Li and Zhang, 2011</xref>).</p>
<p>The development of highly selective I<sub>2</sub>-imidazoline ligands (&gt;1500-fold selectivity for I<sub>2</sub>-sites over α<sub>2</sub>-adrenoceptors), such as 2-styryl-2-imidazoline (LSL 61122; valldemossine or tracizoline) (<xref ref-type="bibr" rid="bibr27-0269881112450785">García-Sevilla et al., 1993</xref>; <xref ref-type="bibr" rid="bibr58-0269881112450785">Ozaita et al., 1997</xref>; <xref ref-type="bibr" rid="bibr59-0269881112450785">Pigini et al., 1997</xref>), 2-(2-benzofuranyl)-2-imidazoline (2-BFI) (<xref ref-type="bibr" rid="bibr53-0269881112450785">Nutt et al., 1995</xref>) and its quinoline analogue 2-(4,5-dihydroimidazol-2-yl)quinoline hydrochloride (BU-224) (<xref ref-type="bibr" rid="bibr35-0269881112450785">Hudson et al., 1997</xref>, <xref ref-type="bibr" rid="bibr36-0269881112450785">1999</xref>), has been instrumental in characterising I<sub>2</sub>-binding sites and their functions. I<sub>2</sub>-imidazoline receptors are widely distributed in the brain (<xref ref-type="bibr" rid="bibr50-0269881112450785">Miralles et al., 1993</xref>; <xref ref-type="bibr" rid="bibr2-0269881112450785">Alemany et al., 1997</xref>; <xref ref-type="bibr" rid="bibr44-0269881112450785">Lione et al., 1998</xref>; <xref ref-type="bibr" rid="bibr38-0269881112450785">Kawamura et al., 2011</xref>) and found in both neurones and glial cells (<xref ref-type="bibr" rid="bibr65-0269881112450785">Regunathan et al., 1993</xref>; <xref ref-type="bibr" rid="bibr55-0269881112450785">Olmos et al., 1994</xref>; <xref ref-type="bibr" rid="bibr67-0269881112450785">Ruggiero et al., 1998</xref>). Notably, selective I<sub>2</sub>-receptor ligands modulate morphine-induced analgaesia and display relevant antinociceptive activity (<xref ref-type="bibr" rid="bibr6-0269881112450785">Boronat et al., 1998</xref>; <xref ref-type="bibr" rid="bibr68-0269881112450785">Sánchez-Blázquez et al., 2000</xref>; <xref ref-type="bibr" rid="bibr30-0269881112450785">Gentili et al., 2006</xref>; <xref ref-type="bibr" rid="bibr19-0269881112450785">Ferrari et al., 2011</xref>; <xref ref-type="bibr" rid="bibr43-0269881112450785">Li et al., 2011</xref>; <xref ref-type="bibr" rid="bibr42-0269881112450785">Li and Zhang, 2011</xref>). Moreover, alterations of I<sub>2</sub>-receptors have been associated with various psychiatric and neurodegenerative disorders (<xref ref-type="bibr" rid="bibr28-0269881112450785">García-Sevilla et al., 1999</xref>; <xref ref-type="bibr" rid="bibr71-0269881112450785">Smith et al., 2009</xref>). Remarkably, stimulation of I<sub>2</sub>-receptors can promote various neuroprotective actions in rats and mice (<xref ref-type="bibr" rid="bibr6-0269881112450785">Boronat et al., 1998</xref>; <xref ref-type="bibr" rid="bibr61-0269881112450785">Qiu and Zheng, 2006</xref>; <xref ref-type="bibr" rid="bibr77-0269881112450785">Wang et al., 2011</xref>). Thus, selective I<sub>2</sub>-ligands were shown to induce neuroprotection in various models of neurotoxicity through blockade of N-methyl-D-aspartate (NMDA) receptors (<xref ref-type="bibr" rid="bibr56-0269881112450785">Olmos et al., 1996</xref>, <xref ref-type="bibr" rid="bibr57-0269881112450785">1999</xref>; <xref ref-type="bibr" rid="bibr49-0269881112450785">Milhaud et al., 2000</xref>; <xref ref-type="bibr" rid="bibr37-0269881112450785">Jiang et al., 2010</xref>), activation of glial cells and production of neurotrophic factors (<xref ref-type="bibr" rid="bibr55-0269881112450785">Olmos et al., 1994</xref>; <xref ref-type="bibr" rid="bibr1-0269881112450785">Alemany et al., 1995</xref>; <xref ref-type="bibr" rid="bibr8-0269881112450785">Casanovas et al., 2000</xref>) or lysosomal membrane stabilization in astrocytes (<xref ref-type="bibr" rid="bibr10-0269881112450785">Choi et al., 2002</xref>).</p>
<p>Other mechanisms of neuroprotection induced by imidazoline drugs may involve the regulation of mitochondrial apoptotic proteins or caspase-3 activity (<xref ref-type="bibr" rid="bibr13-0269881112450785">Dontenwill et al., 2003</xref>; <xref ref-type="bibr" rid="bibr14-0269881112450785">Dupuy et al., 2004</xref>; <xref ref-type="bibr" rid="bibr33-0269881112450785">Han et al., 2010</xref>). Apoptosis is mediated by the extrinsic or death receptor pathway (<xref ref-type="bibr" rid="bibr45-0269881112450785">Lossi and Merighi, 2003</xref>) and the intrinsic or mitochondrial pathway (<xref ref-type="bibr" rid="bibr21-0269881112450785">Galluzzi et al., 2009</xref>). Thus, apoptosis requires the formation of a death-inducing signalling complex (DISC) (e.g. Fas receptor–Fas- associated death domain (FADD) adaptor, initiator caspase-8 and FADD-like interleukin-1β-converting enzyme-inhibitory protein (FLIP<sub>L</sub>)) as well as the involvement of pro-apoptotic mitochondrial factors (e.g. Bax, cytochrome c) that detect and amplify the signals of death receptors. These apoptotic pathways converge to activate executioner caspases (e.g. caspase-3) that cleave vital substrates leading to cell death (<xref ref-type="bibr" rid="bibr41-0269881112450785">Kumar, 2007</xref>). Importantly, Fas-FADD complex and p-Ser194 FADD can also induce non-apoptotic signals (e.g. neuroplasticity) in the brain (<xref ref-type="bibr" rid="bibr75-0269881112450785">Tourneur and Chiocchia, 2010</xref>; <xref ref-type="bibr" rid="bibr64-0269881112450785">Ramos-Miguel et al., 2011</xref>).</p>
<p>To further investigate new signalling pathways and neuroprotective mechanisms associated with I<sub>2</sub>-imidazoline receptors, the acute and chronic effects of selective and non-selective I<sub>2</sub>-drugs on the main components of the extrinsic and intrinsic apoptotic pathways, the activation of pro-apoptotic c-Jun NH<sub>2</sub>-terminal protein kinase (JNK; <xref ref-type="bibr" rid="bibr11-0269881112450785">Dhanasekaran and Reddy, 2008</xref>) and the integrity of the DNA repair enzyme poly-(ADP-ribose)- polymerase-1 (PARP-1; <xref ref-type="bibr" rid="bibr9-0269881112450785">Chaitanya et al., 2010</xref>) were assessed in the rat brain.</p>
</sec>
<sec id="section2-0269881112450785" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section3-0269881112450785">
<title>Drugs</title>
<p>LSL 61122 (2-styryl-2-imidazoline trans form HCl; valldemossine or tracizoline), LSL 60101 [2-(2-benzofuranyl)-2-imidazol HCl], and idazoxan HCl were kindly provided by Ipsen Pharma S.A. (Barcelona, Spain) and the compound retested for structural integrity (<sup>1</sup>H nuclear magnetic resonance spectroscopy) at the University of the Balearic Islands (UIB) core facilities (Dr Gabriel Martorell). 2-BFI [2-(2-benzofuranyl)-2-imidazoline HCl] and its quinoline analogue BU-224 [2-(4,5-dihydroimidazol-2-yl)-quinoline HCl] were purchased from Tocris Bioscience (Avonmouth, UK). All drugs were dosed as HCl salts. The chemical structures of these compounds, their affinities at I<sub>2</sub>-imidazoline receptors and α<sub>2</sub>-adrenoceptors, and their selectivity for I<sub>2</sub>-receptors are shown in <xref ref-type="table" rid="table1-0269881112450785">Table 1</xref>.</p>
<table-wrap id="table1-0269881112450785" position="float">
<label>Table 1.</label>
<caption>
<p>Chemical structures of I<sub>2</sub>-imidazoline ligands, radioligand binding affinities at I<sub>2</sub>-imidazoline receptors and α<sub>2</sub>-adrenoceptors (Ki values in mammal brain tissue) and α<sub>2</sub>/I<sub>2</sub> drug selectivity.</p>
</caption>
<graphic alternate-form-of="table1-0269881112450785" xlink:href="10.1177_0269881112450785-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">I<sub>2</sub>-imidazoline drug</th>
<th align="left">I<sub>2</sub>-receptor Ki (nM)</th>
<th align="left">α<sub>2</sub>-adrenoceptor Ki (nM)</th>
<th align="left">α<sub>2</sub>/I<sub>2</sub> selectivity</th>
<th align="left">Selected references</th>
</tr>
</thead>
<tbody>
<tr>
<td><bold><italic>LSL 61122 (trans form)</italic></bold><break/><inline-graphic xlink:href="10.1177_0269881112450785-img1.tif"/></td>
<td>2.2<break/>2.9<break/>1.6</td>
<td>&gt;10,000<break/>&gt;10,000</td>
<td>&gt;4500<break/>&gt;3500<break/>&gt;6200</td>
<td>Ipsen Pharma data<break/><xref ref-type="bibr" rid="bibr58-0269881112450785">Ozaita et al., 1997</xref><break/><xref ref-type="bibr" rid="bibr59-0269881112450785">Pigini et al., 1997</xref></td>
</tr>
<tr>
<td><bold>2-BFI</bold><break/><inline-graphic xlink:href="10.1177_0269881112450785-img2.tif"/></td>
<td>3.4<break/>6.0<break/>7.5<break/>3.8<break/>7.0<break/>1.7<break/>4.6</td>
<td>5248<break/>&gt;10,000</td>
<td>&gt;1500<break/>&gt;1500<break/>&gt;1300<break/>&gt;2500<break/>&gt;1400<break/>&gt;5500<break/>&gt;2100</td>
<td><xref ref-type="bibr" rid="bibr16-0269881112450785">Eglen et al., 1998</xref><break/>Ipsen Pharma data<break/><xref ref-type="bibr" rid="bibr2-0269881112450785">Alemany et al., 1997</xref><break/><xref ref-type="bibr" rid="bibr58-0269881112450785">Ozaita et al., 1997</xref><break/><xref ref-type="bibr" rid="bibr6-0269881112450785">Boronat et al., 1998</xref><break/><xref ref-type="bibr" rid="bibr44-0269881112450785">Lione et al., 1998</xref><break/><xref ref-type="bibr" rid="bibr5-0269881112450785">Anderson et al., 2005</xref></td>
</tr>
<tr>
<td><bold><italic>BU-224</italic></bold><break/><inline-graphic xlink:href="10.1177_0269881112450785-img3.tif"/></td>
<td>2.7<break/>2.1<break/>12.6</td>
<td>4074</td>
<td>&gt;1500<break/>&gt;1900<break/>&gt;320</td>
<td><xref ref-type="bibr" rid="bibr16-0269881112450785">Eglen et al., 1998</xref><break/><xref ref-type="bibr" rid="bibr44-0269881112450785">Lione et al., 1998</xref><break/><xref ref-type="bibr" rid="bibr5-0269881112450785">Anderson et al., 2005</xref></td>
</tr>
<tr>
<td><bold><italic>LSL 60101</italic></bold><break/><inline-graphic xlink:href="10.1177_0269881112450785-img4.tif"/></td>
<td>356<break/>350</td>
<td>&gt;10,000</td>
<td>&gt;25<break/>&gt;25</td>
<td>Ipsen Pharma data<break/><xref ref-type="bibr" rid="bibr1-0269881112450785">Alemany et al., 1995</xref></td>
</tr>
<tr>
<td><bold><italic>Idazoxan</italic></bold><break/><inline-graphic xlink:href="10.1177_0269881112450785-img5.tif"/></td>
<td>14<break/>22<break/>7.3<break/>29</td>
<td>11<break/>12</td>
<td>0.86<break/>0.55<break/>1.64<break/>0.41</td>
<td><xref ref-type="bibr" rid="bibr47-0269881112450785">Meana et al., 1989</xref><break/><xref ref-type="bibr" rid="bibr50-0269881112450785">Miralles et al., 1993</xref><break/><xref ref-type="bibr" rid="bibr54-0269881112450785">Olmos et al., 1992</xref><break/><xref ref-type="bibr" rid="bibr44-0269881112450785">Lione et al., 1998</xref><break/><xref ref-type="bibr" rid="bibr5-0269881112450785">Anderson et al., 2005</xref></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0269881112450785">
<p>Radioligands used: [<sup>3</sup>H]2-BFI or [<sup>3</sup>H]idazoxan in the presence of (-)-adrenaline for I<sub>2</sub>-imidazoline receptors, and [<sup>3</sup>H]RX821002 or [<sup>3</sup>H]UK14304 (only idazoxan) for α<sub>2</sub>-adrenoceptors. RX821002, 2-(2-methoxy-1,4-benzodioxan-2-yl)-2-imidazoline, also known as 2-methoxy idazoxan. UK14304, 5-bromo-6(2-imidazolin-2-ylamino)quinoxaline, also known as brimonidine.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section4-0269881112450785">
<title>Animals and treatments</title>
<p>Adult male Sprague-Dawley rats (200–250 g) were used. The animals were housed in methacrylate cages, three rats per cage, with wood shavings (Ultrasorb, Panlab s.l., Barcelona, Spain) under controlled conditions of temperature (21°C), humidity (70%) and light/dark cycle (light period: 08:00 to 20:00 h), and they had free access to a standard diet (Panlab A04) and tap water. All animal care and experimental procedures were conducted according to standard ethical guidelines (European Communities Council Directive 86/609/EEC) and approved by the Local Bioethical Committee (UIB). All efforts were made to minimise the number of animals used and their suffering.</p>
<p>For the acute drug treatments, groups of randomly allocated rats received intraperitoneal (i.p.) injections (1 ml/kg body weight) of LSL 61122, 2-BFI, BU-224, LSL 60101 or idazoxan (10 mg/kg, 2 h; <italic>n</italic>=7 for each group). Other groups of rats received idazoxan (10 mg/kg, i.p.) 30 min before LSL 61122 (10 mg/kg, i.p.) to antagonise the acute effects (2 h) of the I<sub>2</sub>-selective drug (<italic>n</italic>=5 for each group). For the chronic experiments the rats were treated with the LSL 61122, 2-BFI, BU-224, LSL 60101 or idazoxan (10 × 10 mg/kg, i.p., 12 h apart) for seven days (<italic>n</italic>=7 for each group). Control rats (<italic>n</italic>=5–10) received 0.9% NaCl (saline; 1 ml/kg, i.p.) in parallel to drug treatments. The acute and chronic dose regimens of I<sub>2</sub>-drugs, and the duration of treatment, were chosen from previous neurochemical (dose-response) studies in rats (e.g. see <xref ref-type="bibr" rid="bibr1-0269881112450785">Alemany et al., 1995</xref>). The animals were killed without anaesthesia by decapitation at the indicated times. The brains were rapidly removed and the cerebral cortex dissected on ice, frozen in liquid nitrogen and then stored at -80°C until the neurochemical assays.</p>
</sec>
<sec id="section5-0269881112450785">
<title>Sample preparation, Western blot analysis and quantification of target proteins</title>
<p>Rat cortical samples were prepared for Western blot analysis as described by <xref ref-type="bibr" rid="bibr22-0269881112450785">García-Fuster et al. (2003</xref>, <xref ref-type="bibr" rid="bibr23-0269881112450785">2007)</xref>. Protein concentration in cortical homogenates was determined with BCA (bicinchoninic acid) assay kit (Pierce Biotechnology, Rockford, IL, USA). Brain proteins (40 µg of total homogenate) were resolved by gel electrophoresis on 10–12% sodium dodecyl sulfate (SDS)-polyacrylamide minigels (Bio-Rad Laboratories, Hercules, CA, USA), which was followed by protein electrotransferred to nitrocellulose membranes (Bio-Rad Laboratories) and other immunoblot standard procedures (<xref ref-type="bibr" rid="bibr23-0269881112450785">García-Fuster et al., 2007</xref>). For the quantification of Fas receptor forms, the transfer buffer also contained 0.1% SDS to better resolve the expression of Fas receptor aggregates (<xref ref-type="bibr" rid="bibr3-0269881112450785">Álvaro-Bartolomé et al., 2010</xref>). After blocking nonspecific protein-binding sites, the membranes were incubated overnight at 4°C in blocking solution with the primary antibody of interest, and the blots were developed with peroxidase-conjugated secondary antibodies, including anti-rabbit or anti-mouse IgG at 1:5,000 dilution for 1 h at 24°C. The primary antibodies with immunoaffinity-purified epitopes are described in <xref ref-type="table" rid="table2-0269881112450785">Table 2</xref>, and were used at the appropriate dilutions (1:750–1:10,000).</p>
<table-wrap id="table2-0269881112450785" position="float">
<label>Table 2.</label>
<caption>
<p>Antibodies used for the detection and quantification of apoptotic proteins and other signalling molecules in rat brain.</p>
</caption>
<graphic alternate-form-of="table2-0269881112450785" xlink:href="10.1177_0269881112450785-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Protein</th>
<th align="left">Antigen</th>
<th align="left">Host</th>
<th align="left">Antibody</th>
<th align="left">Batch</th>
<th align="left">Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fas</td>
<td>Mouse Fas receptor (C-residues)</td>
<td>Rabbit</td>
<td>sc-716</td>
<td>F1306, I110</td>
<td>Santa Cruz, USA</td>
</tr>
<tr>
<td>FADD</td>
<td>Human FADD (28-208 residues)</td>
<td>Rabbit</td>
<td>sc-5559</td>
<td>K1407</td>
<td>Santa Cruz, USA</td>
</tr>
<tr>
<td>p-Ser194 FADD</td>
<td>Human p-FADD (peptide with p-Ser194)</td>
<td>Rabbit</td>
<td>sc-12439R</td>
<td>C072</td>
<td>Santa Cruz, USA</td>
</tr>
<tr>
<td>Caspase-8</td>
<td>Human caspase-8 (217-350 residues)</td>
<td>Rabbit</td>
<td>sc-7890</td>
<td>H134</td>
<td>Santa Cruz, USA</td>
</tr>
<tr>
<td>FLIP-S/L</td>
<td>Human FLIP (1-202 residues)</td>
<td>Mouse</td>
<td>sc-5276</td>
<td>E2207</td>
<td>Santa Cruz, USA</td>
</tr>
<tr>
<td>Bcl-2</td>
<td>Human Bcl-2 (N-residues)</td>
<td>Rabbit</td>
<td>sc-492</td>
<td>C082</td>
<td>Santa Cruz, USA</td>
</tr>
<tr>
<td>Bax</td>
<td>Human Bax (1-171 residues)</td>
<td>Rabbit</td>
<td>sc-493</td>
<td>B012</td>
<td>Santa Cruz, USA</td>
</tr>
<tr>
<td>Cytochrome c</td>
<td>Pigeon cytochrome c (93-104 residues)</td>
<td>Mouse</td>
<td>556433</td>
<td>59671</td>
<td>BD Pharmigen, USA</td>
</tr>
<tr>
<td>p-JNK1/2</td>
<td>Human JNK (peptide with p-Thr183/Tyr185)</td>
<td>Rabbit</td>
<td>9251</td>
<td>11</td>
<td>Cell Signaling, USA</td>
</tr>
<tr>
<td>JNK1/2</td>
<td>Human JNK2 (GST fusion protein)</td>
<td>Rabbit</td>
<td>9252</td>
<td>8</td>
<td>Cell Signaling, USA</td>
</tr>
<tr>
<td>PARP-1</td>
<td>Human PARP-1 (215-228 residues)</td>
<td>Rabbit</td>
<td>512729</td>
<td>D33259</td>
<td>Calbiochem, FRG</td>
</tr>
<tr>
<td>β-actin</td>
<td>Human β-actin (2-16 residues)</td>
<td>Mouse</td>
<td>A1978</td>
<td>14K4840</td>
<td>Sigma Chemical, USA</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0269881112450785">
<p>FADD: Fas associated protein with death domain; FLIP: FADD-like interleukin-1β-converting enzyme-inhibitory protein; JNK 1/2: c-Jun NH<sub>2</sub>-terminal protein kinase 1/2; PARP-1: poly-(ADP-ribose)-polymerase-1.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The characterisation and validation of the primary antibodies in brain tissue have been reported in previous studies (<xref ref-type="bibr" rid="bibr22-0269881112450785">García-Fuster et al., 2003</xref>, <xref ref-type="bibr" rid="bibr23-0269881112450785">2007</xref>, <xref ref-type="bibr" rid="bibr24-0269881112450785">2008a</xref>, <xref ref-type="bibr" rid="bibr25-0269881112450785">2008b</xref>). In particular, Fas receptor was immunodetected as monomeric (~37 kDa), glycosylated (~48–52 kDa) and aggregated (~116–200 kDa) forms in brain tissue. Total FADD was detected as dimeric forms (~51 kDa) and p-Ser194 FADD as oligomeric forms (~116 kDa).</p>
<p>Bound antibody, representing specific immunoreactivity, was detected with an enhanced chemiluminescence (ECL) detection system (Amersham, Buckinghamshire, UK) and visualised by exposure to autoradiographic film (Amersham ECL Hyperfilm). The intensity of protein bands on autoradiograms, measured as integrated optical density, was quantified by densitometric scanning (GS-800 Imaging Densitometer, Bio-Rad Laboratories) as described by <xref ref-type="bibr" rid="bibr23-0269881112450785">García-Fuster et al. (2007)</xref>. The amount of a target protein in brain samples of rats treated with I<sub>2</sub>-imidazoline drugs was compared in the same gel with that of control saline rats. The quantification procedure was repeated three to six times in different gels (each gel with different brain samples from saline- and drug-treated rats). Finally, percentage changes in immunoreactivity with respect to control samples (100%) were calculated for each rat treated with the specific drug in the various gels and the mean value used as a final estimate. As a control for sample loading and protein transfer, the blots were stripped (<xref ref-type="bibr" rid="bibr7-0269881112450785">Boronat et al., 2001</xref>) and reprobed with anti-β-actin monoclonal antibody, and target protein content was normalised to that of β-actin. Activation of JNK1/2 (p-Thr183/Tyr185) was expressed as the ratio of p-protein to total protein and reported as a percentage of that in the corresponding control group.</p>
</sec>
<sec id="section6-0269881112450785">
<title>Functional assay for apoptotic cell death</title>
<p>Poly(ADP-ribose) polymerase-1 (PARP-1) is a sensor of DNA damage with major roles in DNA repair (<xref ref-type="bibr" rid="bibr9-0269881112450785">Chaitanya et al., 2010</xref>). The proteolytic cleavage of nuclear PARP-1 in brain cortex of rats treated with saline or I<sub>2</sub>-imidazoline drugs was monitored with the PARP Cleavage Detection Kit (Calbiochem, Dramstadt, Germany). The death substrate PARP-1 (116 kDa) is cleaved into a specific 85 kDa fragment after activation of caspase-3, which greatly counteracts PARP function as a DNA repairing enzyme (<xref ref-type="bibr" rid="bibr9-0269881112450785">Chaitanya et al., 2010</xref>). The contents of PARP-1 and fragment were quantified by Western blot analysis (<xref ref-type="bibr" rid="bibr25-0269881112450785">García-Fuster et al., 2008b</xref>).</p>
</sec>
<sec id="section7-0269881112450785">
<title>Data and statistical analysis</title>
<p>All series of data were analysed with GraphPad Prism<sup>TM</sup> software, version 4.0 (GraphPad Software, Inc, San Diego, CA, USA). Results are expressed as mean values ± standard error of the mean (SEM). One-way analysis of variance (ANOVA) with a Bonferroni’s post hoc test (multiple comparisons), and Student’s two-tailed <italic>t</italic>-test were used for the statistical evaluations. The level of significance was chosen as <italic>p</italic> ≤0.05.</p>
</sec>
</sec>
<sec id="section8-0269881112450785" sec-type="results">
<title>Results</title>
<sec id="section9-0269881112450785">
<title>Acute and chronic effects of I<sub>2</sub>-imidazoline ligands on Fas receptor, FADD adaptor and other death-inducing signalling components (DISC) in the brain</title>
<p>The acute treatment of rats with LSL 61122 (10 mg/kg, 2 h), compared with saline solution administration, decreased the content of Fas receptor aggregates (26%) and p-Ser194 FADD (26%) in brain cortex (<xref ref-type="fig" rid="fig1-0269881112450785">Figure 1A</xref>). Acute LSL 61122 did not alter the content of monomeric or glycosylated Fas (data not shown) or that of FADD adaptor (<xref ref-type="fig" rid="fig1-0269881112450785">Figure 1A</xref>). Chronic treatment with LSL 61122 (10 mg/kg, every 12 h for seven days) was not associated with significant changes in Fas receptor forms, FADD or p-Ser194 FADD (<xref ref-type="fig" rid="fig1-0269881112450785">Figure 1A</xref>).</p>
<fig id="fig1-0269881112450785" position="float">
<label>Figure 1.</label>
<caption>
<p>Acute and chronic effects of (A) LSL 61122, (B) 2-BFI and (C) BU-224 on Fas receptor, FADD adaptor and p-Ser194 FADD immunodensities in rat cerebral cortex. Groups of treatments: saline (<italic>n</italic>=10), acute I<sub>2</sub>-drugs (10 mg/kg, i.p., 2 h; n=7), chronic I<sub>2</sub>-drugs (10 mg/kg, i.p., every 12 h for seven days; <italic>n</italic>=7). Columns are means±SEM of <italic>n</italic> experiments per group with an animal per experiment, and expressed as a percentage of saline-treated rats (control group). One-way ANOVA detected significant differences between the groups of treatments for each I<sub>2</sub>-drug and target protein, except in A for FADD (F values, at least <italic>p</italic> &lt;0.01). *p &lt;0.05 **p &lt;0.01; ***<italic>p</italic> &lt;0.001 when compared with the corresponding control group (ANOVA followed by Bonferroni’s test). Right panels (A, B, C): representative immunoblots of Fas receptor aggregates, dimeric FADD and oligomeric p-Ser194 FADD for each set of experiments, and a representative immunoblot for β-actin as a loading control (saline samples in duplicate; I<sub>2</sub>-drug samples in triplicate). The molecular masses of target proteins were estimated from referenced standards.</p>
<p>LSL: 2-styryl-2-imidazoline; BFI: 2-(2-benzofuranyl)-2-imidazoline; BU-224: 2-(4,5-dihydroimidazol-2-yl)quinolinehydrochloride; FADD: Fas associated protein with death domain; i.p.: intraperitoneal; ANOVA: analysis of variance.</p>
</caption>
<graphic xlink:href="10.1177_0269881112450785-fig1.tif"/>
</fig>
<p>Acute 2-BFI (10 mg/kg, 2 h) increased Fas receptor aggregates (51%), FADD (35%) and p-Ser194 FADD (40%) in rat brain cortex (<xref ref-type="fig" rid="fig1-0269881112450785">Figure 1B</xref>). In contrast, chronic 2-BFI (10 mg/kg, every 12 h for seven days) markedly decreased FADD content (47%) without altering that of Fas aggregates or p-Ser194 FADD (<xref ref-type="fig" rid="fig1-0269881112450785">Figure 1B</xref>).</p>
<p>Acute BU-224 (10 mg/kg, 2 h; the quinoline analogue of 2-BFI) decreased Fas receptor aggregates (15%) and p-Ser194 FADD (43%), but not FADD, in rat brain cortex (<xref ref-type="fig" rid="fig1-0269881112450785">Figure 1C</xref>). Chronic BU-224 (10 mg/kg, every 12 h for seven days) reduced the content of Fas receptor aggregates (20%) and FADD (54%) but not that of p-Ser194 FADD (<xref ref-type="fig" rid="fig1-0269881112450785">Figure 1C</xref>).</p>
<p>The acute treatments of rats (10 mg/kg, 2 h) with LSL 60101 (the imidazole analogue of 2-BFI with a lesser affinity for I<sub>2</sub>-sites; <xref ref-type="table" rid="table1-0269881112450785">Table 1</xref>) and idazoxan (a mixed I<sub>2</sub>/α<sub>2</sub>-ligand; <xref ref-type="table" rid="table1-0269881112450785">Table 1</xref>) did not alter the content of Fas receptor forms, FADD or p-Ser194 FADD in brain cortex (data not shown). Similarly, chronic LSL 60101 and idazoxan (10 mg/kg, every 12 h for seven days) were not associated with significant changes in the contents of Fas receptor forms and FADD adaptor in rat brain cortex (data not shown).</p>
<p>Notably, chronic treatment with 2-BFI and BU-224, but not LSL 61122, increased the ratio of p-Ser194 FADD to total FADD (an index of non-apoptotic activity) in the same rat cortical samples (p-FADD/FADD ratio; chronic saline: 1.01 ± 0.05; chronic 2-BFI: 1.60 ± 0.11, <italic>p</italic> &lt; 0.001; chronic BU-224: 2.49 ± 0.39, <italic>p</italic> &lt; 0.005; chronic LSL 61122: 1.11 ± 0.25, <italic>p</italic> &gt; 0.05). In contrast, acute BU-224, but not 2-BFI or LSL 61122, decreased p-Ser194 FADD/FADD ratio in rat brain cortex (acute saline: 1.01 ± 0.11; acute BU 224: 0.59 ± 0.08, <italic>p</italic> &lt; 0.05).</p>
<p>In the extrinsic apoptotic pathway, Fas-FADD complex together with caspase-8 and FLIP<sub>L</sub> conform to the DISC. Acute treatment with LSL 61122, but not with 2-BFI or BU-224, reduced the content of caspase-8 in rat brain cortex (22%) (<xref ref-type="fig" rid="fig2-0269881112450785">Figure 2A</xref>). Acutely, these selective I<sub>2</sub>-drugs did not alter FLIP<sub>L</sub> content (<xref ref-type="fig" rid="fig2-0269881112450785">Figure 2B</xref>). Chronic 2-BFI, but not BU-224, decreased the content of caspase-8 (30%) and that of FLIP<sub>L</sub> (23%) in rat brain cortex (<xref ref-type="fig" rid="fig2-0269881112450785">Figure 2A</xref>). Chronic LSL 61112 was not associated with alterations of caspase-8 but it increased FLIP<sub>L</sub> content (23%) (<xref ref-type="fig" rid="fig2-0269881112450785">Figure 2A</xref> and <xref ref-type="fig" rid="fig2-0269881112450785">Figure 2B</xref>).</p>
<fig id="fig2-0269881112450785" position="float">
<label>Figure 2.</label>
<caption>
<p>Acute and chronic effects of LSL 61122, 2-BFI and BU-224 on (A) caspase-8 and (B) FLIP<sub>L</sub> immunodensities in rat cerebral cortex. Groups of treatments: saline (<italic>n</italic>=10), acute I<sub>2</sub>-drugs (10 mg/kg, i.p., 2 h; <italic>n</italic>=7), chronic I<sub>2</sub>-drugs (10 mg/kg, i.p., every 12 h for seven days; <italic>n</italic>=7). Columns are means±SEM of n experiments per group with an animal per experiment and expressed as a percentage of saline-treated rats (control group). One-way ANOVA detected significant differences between the groups of treatments for I<sub>2</sub>-drug and target protein, except for BU-224 (F values, at least <italic>p</italic> &lt;0.05). *<italic>p</italic> &lt;0.05 **<italic>p</italic> &lt;0.01 when compared with the corresponding control group (ANOVA followed by Bonferroni’s test). Right panels (A, B): representative immunoblots of caspase-8 and FLIP<sub>L</sub> for each set of experiments and a representative immunoblot for β-actin as a loading control (saline samples in duplicate; I<sub>2</sub>-drug samples in triplicate). The molecular masses of target proteins were estimated from referenced standards.</p>
<p>LSL: 2-styryl-2-imidazoline; BFI: 2-(2-benzofuranyl)-2-imidazoline; BU-224: 2-(4,5-dihydroimidazol-2-yl)quinolinehydrochloride; FLIP: FADD-like interleukin-1β-converting enzyme-inhibitory protein; i.p.: intraperitoneal; ANOVA: analysis of variance.</p>
</caption>
<graphic xlink:href="10.1177_0269881112450785-fig2.tif"/>
</fig>
</sec>
<sec id="section10-0269881112450785">
<title>Acute and chronic effects of I<sub>2</sub>-imidazoline ligands on Bcl-2, Bax and cytochrome c in the brain</title>
<p>The acute treatment of rats with LSL 61122 (10 mg/kg, 2 h) decreased the content of Bcl-2 (44%) and Bax (35%) in brain cortex (<xref ref-type="fig" rid="fig3-0269881112450785">Figure 3A</xref>). In contrast, chronic treatment with LSL 61122 (10 mg/kg, every 12 h for seven days) markedly increased Bcl-2 content (53%) but not that of Bax (<xref ref-type="fig" rid="fig3-0269881112450785">Figure 3A</xref>).</p>
<fig id="fig3-0269881112450785" position="float">
<label>Figure 3.</label>
<caption>
<p>Acute and chronic effects of (A) LSL 61122, (B) 2-BFI and (C) BU-224 on Bcl-2, Bax and cytochrome c (Cyt c) immunodensities in rat cerebral cortex. Groups of treatments: saline (<italic>n</italic>=10), acute I<sub>2</sub>-drugs (10 mg/kg, i.p., 2 h; n=7), chronic I<sub>2</sub>-drugs (10 mg/kg, i.p., every 12 h for seven days; <italic>n</italic>=7). Columns are means±SEM of <italic>n</italic> experiments per group with an animal per experiment, and expressed as a percentage of saline-treated rats (control group). One-way ANOVA detected significant differences between the groups of treatments for I<sub>2</sub>-drug and target protein, except in C for Bcl-2 (F values, at least <italic>p</italic> &lt;0.01). *<italic>p</italic> &lt;0.05 **<italic>p</italic> &lt;0.01; ***<italic>p</italic> &lt;0.001 when compared with the corresponding control group (ANOVA followed by Bonferroni’s test). Right panels (A, B, C): representative immunoblots of Bcl-2, Bax and Cyt c for each set of experiments and a representative immunoblot for β-actin as a loading control (saline samples in duplicate; I<sub>2</sub>-drug samples in triplicate). The molecular masses of target proteins were estimated from referenced standards.</p>
<p>LSL: 2-styryl-2-imidazoline; BFI: 2-(2-benzofuranyl)-2-imidazoline; BU-224: 2-(4,5-dihydroimidazol-2-yl)quinolinehydrochloride; i.p.: intraperitoneal; ANOVA: analysis of variance.</p>
</caption>
<graphic xlink:href="10.1177_0269881112450785-fig3.tif"/>
</fig>
<p>Thus, chronic LSL 61122 increased the ratio of anti-apoptotic Bcl-2 to pro-apoptotic Bax (an index that measures the balance between cell survival and cell death) in brain cortex (Bcl-2/Bax ratio; saline: 0.99 ± 0.07%; LSL: 1.54 ± 0.16%, <italic>p</italic> &lt; 0.01). Moreover, acute and chronic LSL 61122 induced significant decreases in the content of cytochrome c, a potent caspase-3 activator, in rat brain cortex (24% and 38%, respectively, <italic>p</italic> &lt; 0.01) (<xref ref-type="fig" rid="fig3-0269881112450785">Figure 3A</xref>).</p>
<p>Acute 2-BFI (10 mg/kg, 2 h) increased Bcl-2 content (35%) but not that of Bax in rat brain cortex (<xref ref-type="fig" rid="fig3-0269881112450785">Figure 3B</xref>). Chronic 2-BFI did not alter Bcl-2 but decreased Bax (20%) (<xref ref-type="fig" rid="fig3-0269881112450785">Figure 3B</xref>). Chronic 2-BFI did not significantly alter the ratio of Bcl-2 to Bax. Chronic, but not acute, 2-BFI treatment reduced cytochrome c content in brain cortex (28%) (<xref ref-type="fig" rid="fig3-0269881112450785">Figure 3B</xref>).</p>
<p>Acute BU-224 (10 mg/kg, 2 h) did not alter the content of Bcl-2, Bax or cytochrome c in rat brain cortex (<xref ref-type="fig" rid="fig3-0269881112450785">Figure 3C</xref>). However, chronic BU-224 decreased Bax (23%) and cyrochrome c (22%) content without altering that of Bcl-2 (<xref ref-type="fig" rid="fig3-0269881112450785">Figure 3C</xref>). Chronic 2-BFI did not significantly alter the ratio of Bcl-2 to Bax.</p>
<p>Acute treatments of rats with LSL 60101 and idazoxan (see above) did not significantly alter the contents of Bcl-2, Bax and cytochrome c, or the ratio of Bcl-2 to Bax in brain cortex (data not shown). Similarly, chronic LSL 60101 and idazoxan (10 mg/kg, every 12 h for seven days) were not associated with significant changes in the content of Bcl-2 protein in rat brain cortex (data not shown).</p>
</sec>
<sec id="section11-0269881112450785">
<title>Prevention by idazoxan of LSL 61122-induced down-regulation of Bax and cytochrome c in the brain</title>
<p>Pretreatment of rats (30 min) with idazoxan (10 mg/kg, i.p.) fully prevented the acute down-regulation of Bax (33%) and cytochrome c (31%) induced by the selective I<sub>2</sub>-ligand LSL 61122 (2 h) in brain cortex (<xref ref-type="fig" rid="fig4-0269881112450785">Figure 4</xref>). Idazoxan by itself did not modify the basal content of Bax or cytochrome c in rat brain cortex (<xref ref-type="fig" rid="fig4-0269881112450785">Figure 4</xref>).</p>
<fig id="fig4-0269881112450785" position="float">
<label>Figure 4.</label>
<caption>
<p>Effects of pretreatment with idazoxan on LSL 61122-induced down-regulation of mitochondrial Bax and cytochrome c (Cyt c) in rat cerebral cortex. Groups of treatments: saline (<italic>n</italic>=5), LSL 61122 (10 mg/kg, i.p., 2 h; <italic>n</italic>=5), idazoxan (10 mg/kg, i.p.) alone (2 h, <italic>n</italic>=5) or 30 min before LSL 61122 (n=5). Columns are means±SEM of n experiments per group with an animal per experiment and expressed as a percentage of saline-treated rats (control group). One-way ANOVA detected a significant difference between the groups of treatments for Bax [F(3,16)=16.07, <italic>p</italic> &lt;0.0001] and Cyt c [F(3,16)=4.86, <italic>p</italic> &lt;0.01]. *<italic>p</italic> &lt;0.05; **<italic>p</italic> &lt;0.01 when compared with the corresponding control group, and †<italic>p</italic> &lt;0.05; †††<italic>p</italic> &lt;0.001 when compared with the corresponding LSL 61122 group (ANOVA followed by Bonferroni’s test). Bottom panel: representative immunoblots of Bax and Cyt c for each set of experiments (Idx: idazoxan; LSL: LSL 61122; Idx+LSL: idazoxan plus LSL61122) and a representative immunoblot for β-actin as a loading control (saline and I<sub>2</sub>-drug samples in triplicate). The molecular masses of target proteins were estimated from referenced standards.</p>
<p>LSL: 2-styryl-2-imidazoline; i.p.: intraperitoneal; ANOVA: analysis of variance.</p>
</caption>
<graphic xlink:href="10.1177_0269881112450785-fig4.tif"/>
</fig>
</sec>
<sec id="section12-0269881112450785">
<title>Acute and chronic effects of selective I<sub>2</sub>-imidazoline ligands on the activation of pro-apoptotic JNK1/2 and the cleavage of PARP-1 in the brain</title>
<p>The acute (10 mg/kg, 2 h) and chronic (10 mg/kg, every 12 h for seven days) treatments of rats with LSL 61122, 2-BFI and BU-224 did not significantly alter the activation of JNK1/2 (ratio of p-Thr183/Tyr185 JNK to total JNK) in brain cortex (<xref ref-type="fig" rid="fig5-0269881112450785">Figure 5A</xref>, immunoblots shown for chronic treatments).</p>
<fig id="fig5-0269881112450785" position="float">
<label>Figure 5.</label>
<caption>
<p>Acute and chronic effects of 2-BFI, BU-224 LSL 61122 on (A) the activation of JNK1/2 (shown as the ratio of p-Thr183/Tyr185 JNK1/2 to total JNK1/2) and (B) the pattern of proteolytic cleavage of nuclear PARP-1 in rat cerebral cortex. Groups of treatments: saline (<italic>n</italic>=10), acute I<sub>2</sub>-drugs (10 mg/kg, i.p., 2 h; <italic>n</italic>=7), chronic I<sub>2</sub>-drugs (10 mg/kg, i.p., every 12 h for seven days; <italic>n</italic>=7). Columns are means±SEM of <italic>n</italic> experiments per group with an animal per experiment and expressed as a percentage of saline-treated rats (control group). One-way ANOVA did not detect significant differences between the groups of treatments for any I<sub>2</sub>-drug (F values, <italic>p</italic> &gt;0.05). Bottom panels (A, B): (A) representative immunoblots of p-JNK1/2 and total JNK1/2 for each set of chronic treatments (saline samples in duplicate; I<sub>2</sub>-drug samples in triplicate); (B) representative immunoblot of PARP-1 (~116 kDa) cleavage (~85 kDa fragment) for each set of chronic treatments (saline and I<sub>2</sub>-drug samples in duplicate). PC: positive control (etoposide-induced apoptosis in HL60 cells). NC: negative control (whole cell extract of human HL60 leukaemia cells). IOD: integrated optical density. The molecular masses of target proteins were estimated from referenced standards.</p>
<p>BFI: 2-(2-benzofuranyl)-2-imidazoline; BU-224: 2-(4,5-dihydroimidazol-2-yl)quinolinehydrochloride; LSL: 2-styryl-2-imidazoline; JNK1/2: c-Jun NH<sub>2</sub>-terminal protein kinase; PARP-1: poly-(ADP-ribose)-polymerase-1; i.p.: intraperitoneal; ANOVA: analysis of variance.</p>
</caption>
<graphic xlink:href="10.1177_0269881112450785-fig5.tif"/>
</fig>
<p>On the other hand, the proteolytic cleavage of nuclear PARP-1, assessed through the quantification of 85 kDa fragment, was very similar in saline- and I<sub>2</sub>-imidazoline ligand-treated rats (relative fragment content; saline: 33 ± 7%; LSL 61122: 28 ± 1%; 2-BFI: 28 ± 2%; BU-224: 30 ± 1%) (<xref ref-type="fig" rid="fig5-0269881112450785">Figure 5B</xref>). The total amount of PARP-1 was not altered by these drug treatments (<xref ref-type="fig" rid="fig5-0269881112450785">Figure 5B</xref>, immunoblots shown for chronic treatments).</p>
</sec>
</sec>
<sec id="section13-0269881112450785" sec-type="discussion">
<title>Discussion</title>
<p>The major finding of this study demonstrates that chronic treatments with selective I<sub>2</sub>-imidazoline receptor ligands (LSL 61112, 2-BFI, BU-224) down-regulated the content of pro-apoptotic FADD adaptor, Bax and cytochrome c in rat brain cortex. These results indicate that I<sub>2</sub>-imidazoline drugs might induce neuroprotective actions through inhibition of key components of canonical apoptotic signalling in the brain (<xref ref-type="fig" rid="fig6-0269881112450785">Figure 6</xref>).</p>
<fig id="fig6-0269881112450785" position="float">
<label>Figure 6.</label>
<caption>
<p>Schematic diagram illustrating the main components of the extrinsic (Fas death receptor) and intrinsic (mitochondrial) apoptotic pathways. See Results and Discussion for specific findings and comments on the acute and chronic regulation of apoptotic proteins by selective I<sub>2</sub>-imidazoline drugs in rat brain.</p>
</caption>
<graphic xlink:href="10.1177_0269881112450785-fig6.tif"/>
</fig>
<p>After induction of Fas receptor aggregates, a DISC is formed by recruitment of FADD adaptor, initiator caspase-8 and FLIP<sub>L</sub>, a catalytically inactive caspase-8 homologue, which provides a molecular scaffold to transmit death signals with the final activation of effector caspases, such as caspase-3 (<xref ref-type="bibr" rid="bibr25-0269881112450785">García-Fuster et al., 2008b</xref>). The acute treatments of rats with LSL 61122 and BU-224 reduced the content of Fas aggregates, p-Ser194 FADD (but not total FADD) and caspase-8 (only with LSL 61122) in brain cortex, which could suggest an attenuation of death receptor signals. In contrast, acute 2-BFI markedly increased Fas aggregates, FADD and p-Ser194 FADD in rat brain cortex. The acute effect of 2-BFI, which suggests the induction of pro-apoptotic actions, might be related to its known indirect dopaminergic activity (<xref ref-type="bibr" rid="bibr36-0269881112450785">Hudson et al., 1999</xref>; <xref ref-type="bibr" rid="bibr69-0269881112450785">Sastre-Coll et al., 2001</xref>). In fact, the acute activation of the dopaminergic system, directly (D<sub>2</sub> receptor agonist) or indirectly (cocaine), has been reported to increase the content of pro-apoptotic FADD in the rat brain (<xref ref-type="bibr" rid="bibr26-0269881112450785">García-Fuster et al., 2009</xref>; <xref ref-type="bibr" rid="bibr4-0269881112450785">Álvaro-Bartolomé et al., 2011</xref>). However, BU-224 was shown to be much more effective than 2-BFI (20 mg/kg for both drugs) on dopamine release in rat striatum (<xref ref-type="bibr" rid="bibr36-0269881112450785">Hudson et al., 1999</xref>), suggesting that other mechanisms, including pharmacokinetic factors, could be involved in the contrasting acute effects of these drugs (with similar affinities for I<sub>2</sub>-sites; <xref ref-type="table" rid="table1-0269881112450785">Table 1</xref>) on Fas/FADD complex. Notably, however, chronic treatments with 2-BFI and BU-224 were associated with decreases of Fas aggregates, FADD adaptor and/or caspase-8 (only with 2-BFI), which indicated that these selective I<sub>2</sub>-imidazoline drugs down-regulated key signalling components of the extrinsic apoptotic pathway in the brain. Chronic LSL 61122 only increased cortical FLIP<sub>L</sub> content, an anti-apoptotic factor that was reduced by chronic 2-BFI. Importantly, chronic 2-BFI and BU-229 also increased the ratio of p-Ser194 FADD to FADD in rat brain cortex. An altered balance between pro-apoptotic FADD and non-apoptotic p-Ser194 FADD (increased p-FADD/FADD ratio; <xref ref-type="fig" rid="fig6-0269881112450785">Figure 6</xref>) could further favour the neuroplastic/neuroprotective actions induced by some I<sub>2</sub>-imidazoline drugs (e.g. see <xref ref-type="bibr" rid="bibr64-0269881112450785">Ramos-Miguel et al., 2011</xref>).</p>
<p>In the intrinsic apoptotic pathway (<xref ref-type="fig" rid="fig6-0269881112450785">Figure 6</xref>), the acute treatments of rats with selective and nonselective I<sub>2</sub>-imidazoline drugs (LSL 61122, 2-BFI, BU-224, LSL 60101, idazoxan) resulted in contrasting changes or no alterations in the content of anti-apoptotic (Bcl-2) or pro-apoptotic (Bax and cytochrome c, both potent caspase-3 activators) mitochrondrial proteins in brain cortex. Importantly, the acute down-regulation of Bax and cytochrome c induced by the selective I<sub>2</sub>-ligand LSL 61122 was antagonised by idazoxan (see comments below). Notably, chronic treatments with LSL 61122, 2-BFI and BU-224 were associated with decreases of pro-apoptotic Bax and/or cytochrome c in rat brain cortex. Furthermore, chronic LSL 61122 also increased the ratio of Bcl-2 to Bax, an index that measures the balance between cell survival and cell death (<xref ref-type="bibr" rid="bibr40-0269881112450785">Korsmeyer et al., 1993</xref>), which suggests that this I<sub>2</sub>-imidazoline drug preferentially attenuates mitochondrial apoptotic signalling (chronic LSL 61122 only increased anti-apoptotic FLIP<sub>L</sub> in the extrinsic pathway). Recently, acute 2-BFI (1–6 mg/kg) was also reported to increase Bcl-2 expression in rat brain cortex conferring neuroprotection (i.e. reduction of cell death and infarct size with 1–3 mg/kg) against transient cerebral ischemia (<xref ref-type="bibr" rid="bibr33-0269881112450785">Han et al., 2010</xref>). In the current study, acute 2-BFI (10 mg/kg) also up-regulated the content of Bcl-2 protein in the cerebral cortex of naïve rats. Reinforcing the neuroprotective actions of I<sub>2</sub>-imidazoline drugs in the brain, the acute and/or chronic treatments with LSL 61122, 2-BFI and BU-224 were not associated with aberrant activation of pro-apoptotic JNK1/2 (<xref ref-type="bibr" rid="bibr11-0269881112450785">Dhanasekaran and Reddy, 2008</xref>) or increased proteolytic cleavage of nuclear PARP-1, a hallmark of apoptosis, which is mainly mediated by caspase-3 (<xref ref-type="bibr" rid="bibr41-0269881112450785">Kumar, 2007</xref>; <xref ref-type="bibr" rid="bibr9-0269881112450785">Chaitanya et al., 2010</xref>) (<xref ref-type="fig" rid="fig6-0269881112450785">Figure 6</xref>). In fact, 2-BFI treatment was reported to reduce the number of caspase-3 positive cells in ischemia-induced rat brain injury (<xref ref-type="bibr" rid="bibr32-0269881112450785">Han et al., 2009</xref>).</p>
<p>It is important to note that the compounds BU-224 and 2-BFI are highly selective ligands for I<sub>2</sub>-binding sites over I<sub>1</sub>-binding sites (BU-224 is 832-fold selective for I<sub>2</sub>-sites; <xref ref-type="bibr" rid="bibr36-0269881112450785">Hudson et al., 1999</xref>). I<sub>1</sub>-imidazoline receptors have also been involved in the in vitro regulation of cell death in PC12 pheochromocytoma cells (<xref ref-type="bibr" rid="bibr13-0269881112450785">Dontenwill et al., 2003</xref>; <xref ref-type="bibr" rid="bibr14-0269881112450785">Dupuy et al., 2004</xref>). In an early study, stimulation of I<sub>1</sub>-imidazoline receptors with moxonidine was shown to increase pro-apoptotic JNK enzymatic activity in PC12 cells, which was prevented with the I<sub>1</sub>-receptor antagonist efaroxan (<xref ref-type="bibr" rid="bibr15-0269881112450785">Edwards et al., 2001</xref>). In contrast, the selective I<sub>2</sub>-ligands 2-BFI, BU-224 and LSL 61122 did not activate pro-apoptotic JNK1/2 in rat brain cortex (current results). Although the I<sub>1</sub>-protein imidazoline receptor antisera (IRAS)/nischarin can function as an anti-apoptotic molecule in PC12 cells reducing the activity of caspase-3 (<xref ref-type="bibr" rid="bibr13-0269881112450785">Dontenwill et al., 2003</xref>), other evidence indicates that the selective I<sub>1</sub>-ligand benazoline potentiates PC12 cell death (through increased caspase-3 activity, blocked by efaroxan) induced by serum deprivation (<xref ref-type="bibr" rid="bibr14-0269881112450785">Dupuy et al., 2004</xref>). Recently, chronic moxonidine treatment (9.6 mg/kg/day for one month) has been reported to induce anti-apoptotic actions (Bcl-2 increased; Bax unaltered) in the hamster heart (<xref ref-type="bibr" rid="bibr72-0269881112450785">Stabile et al., 2011</xref>). It therefore appears that the chronic activation of I<sub>2</sub>- or I<sub>1</sub>-imidazoline receptors is associated with anti-apoptotic actions in vivo. In the present study, it is also worth noting that the compounds LSL 60101 (the imidazole analogue of 2-BFI) and idazoxan (a mixed I<sub>2</sub>/α<sub>2</sub>-receptor ligand) did not alter the content of pro- or anti-apoptotic proteins of the extrinsic and intrinsic apoptotic pathways (see comments below).</p>
<p>A shortcoming in the assessment of the in vivo effects of I<sub>2</sub>-imidazoline drugs is the difficulty in ascribing agonist or antagonist properties for a given drug at I<sub>2</sub>-receptors. An early study proposed a functional approach to address this problem: the modulation of morphine analgaesia by I<sub>2</sub>-ligands, which could discriminate agonist and antagonist drug activities according to classic receptor pharmacology (<xref ref-type="bibr" rid="bibr68-0269881112450785">Sánchez-Blázquez et al., 2000</xref>). It is known that idazoxan displays very similar affinities for I<sub>2</sub>-imidazoline sites and α<sub>2</sub>-adrenoceptor agonist or antagonist sites (<xref ref-type="table" rid="table1-0269881112450785">Table 1</xref>). In functional studies in rats, idazoxan has been demonstrated to be a competitive (orthosteric) antagonist at α<sub>2</sub>-adrenoceptors (e.g. see <xref ref-type="bibr" rid="bibr48-0269881112450785">Menargues et al., 1990</xref>; <xref ref-type="bibr" rid="bibr29-0269881112450785">García-Vallejo et al., 1994</xref>). In functional studies in mice (<xref ref-type="bibr" rid="bibr68-0269881112450785">Sánchez-Blázquez et al., 2000</xref>), agmatine (an endogenous I<sub>2</sub>-ligand), LSL 61122, 2-BFI and LSL 60101 behaved as I<sub>2</sub>-receptor agonists, and idazoxan and BU-224 as silent I<sub>2</sub>-receptor antagonists. Thus idazoxan and BU-224 (inactive by themselves) completely blocked the potentiation of morphine antinociception induced by agmatine, LSL 61122 and 2-BFI (<xref ref-type="bibr" rid="bibr68-0269881112450785">Sánchez-Blázquez et al., 2000</xref>). Similarly, idazoxan also antagonised the potentiation of morphine analgaesia induced by the selective I<sub>2</sub>-ligand phenyzoline (<xref ref-type="bibr" rid="bibr30-0269881112450785">Gentili et al., 2006</xref>). Furthermore, CR4056, a novel I<sub>2</sub>-imidazoline drug, also showed analgesic efficacy which was blocked by idazoxan (<xref ref-type="bibr" rid="bibr19-0269881112450785">Ferrari et al., 2011</xref>). Therefore, idazoxan is a reliable I<sub>2</sub>-receptor antagonist to fully assess the in vivo effects of selective I<sub>2</sub>-receptor agonists. In this context, chronic treatment of rats with idazoxan (10 mg/kg, every 12 h for seven days) was shown to increase the density of I<sub>2</sub>-binding sites in brain cortex (<xref ref-type="bibr" rid="bibr54-0269881112450785">Olmos et al., 1992</xref>, <xref ref-type="bibr" rid="bibr55-0269881112450785">1994</xref>). This up-regulation of brain I<sub>2</sub>-receptor number after repeated idaxozan is consistent with the expected effect of a chronic treatment with an antagonist.</p>
<p>In the current in vivo study, the selective I<sub>2</sub>-imidazoline ligand LSL 61122 also acted as an I<sub>2</sub>-receptor agonist (acute down-regulation of pro-apoptotic Bax and cytochrome c) and idazoxan as a silent I<sub>2</sub>-receptor antagonist (i.e. idazoxan did not modify the basal content of Bax or cytochrome c, but it blocked the effects of LSL 61122). Upon chronic treatments, LSL 61122, 2-BFI and BU-224 also appeared to behave as I<sub>2</sub>-receptor agonists (i.e. sustained down-regulation of Bax and/or cytochrome c). However, these effects of BU-224 on apoptotic signalling (similar to those of 2-BFI) contrast with other findings indicating that this drug behaved as an I<sub>2</sub>-receptor antagonist in antinociceptive assays in rats (<xref ref-type="bibr" rid="bibr68-0269881112450785">Sánchez-Blázquez et al., 2000</xref>; <xref ref-type="bibr" rid="bibr73-0269881112450785">Thorn et al., 2011</xref>). In electrophysiological studies, BU-224 was reported to induce spinal analgaesia (i.e. inhibition of dorsal horn neurones) in rats acting as an I<sub>2</sub>-receptor agonist, the effect being blocked by idazoxan (<xref ref-type="bibr" rid="bibr12-0269881112450785">Díaz et al., 1997</xref>). More recently, BU-224 and 2-BFI were also shown to induce dose-dependent antinociceptive effects in rats, which were antagonised by idazoxan but not by the α<sub>2</sub>-adrenoceptor antagonist yohimbine (<xref ref-type="bibr" rid="bibr43-0269881112450785">Li et al., 2011</xref>). These findings appear to agree well with the current study which indicates that BU-224 behaves as an I<sub>2</sub>-receptor agonist modulating the content of mitochondrial apoptotic proteins. BU-224 (<xref ref-type="bibr" rid="bibr20-0269881112450785">Finn et al., 2003</xref>) and 2-BFI (<xref ref-type="bibr" rid="bibr74-0269881112450785">Tonello et al., 2012</xref>) are also reported to display antidepressant-like activity most probably acting as I<sub>2</sub>-receptor agonists. In the current study, LSL 60101 (the imidazole analogue of 2-BFI) was an inactive compound as a modulator of apoptotic signalling, but it behaved as an I<sub>2</sub>-receptor agonist potentiating morphine analgaesia in mice (<xref ref-type="bibr" rid="bibr68-0269881112450785">Sánchez-Blázquez et al., 2000</xref>) but not in rats (<xref ref-type="bibr" rid="bibr6-0269881112450785">Boronat et al., 1998</xref>). Chronic treatment of rats with LSL 60101 was shown to up-regulate the density of I<sub>2</sub>-binding sites in brain cortex (<xref ref-type="bibr" rid="bibr1-0269881112450785">Alemany et al., 1995</xref>), which suggests that this compound could also behave as an I<sub>2</sub>-receptor antagonist (see above comment for idazoxan). It therefore appears that some I<sub>2</sub>-imidazoline ligands (e.g. BU-224 and LSL 60101), due to species-related variations and/or chosen target for analysis and/or differences in experimental paradigms, can behave as I<sub>2</sub>-receptor agonists, low efficacy I<sub>2</sub>-(partial) agonists or I<sub>2</sub>-receptor antagonists.</p>
<p>In conclusion, the sustained stimulation of I<sub>2</sub>-imidazoline receptors with selective drugs might be associated with neuroprotective actions through inhibition of key components of canonical apoptotic signalling (FADD, Bax and/or cytochrome c) and up-regulation of survival anti-apoptotic factors (p-Ser194 FADD/FADD and/or Bcl-2/Bax ratios), which in the long-term could dampen cell death in the brain. These anti-apoptotic mechanisms may work in concert with other molecular mechanisms of neuroprotection (e.g. blockade of NMDA receptors; <xref ref-type="bibr" rid="bibr57-0269881112450785">Olmos et al., 1999</xref>) that are engaged by selective I<sub>2</sub>-imidazoline drugs.</p>
</sec>
</body>
<back>
<ack>
<p>The authors thank Dr Rossend Obach and Dr Ángel Menargues (Ipsen Pharma S.A., Barcelona) for gifts of LSL compounds, and Dr Gabriel Martorell (Universitat de les Illes Balears) for NMR analyses of LSL 61122 and LSL 60101. Dr Celia Garau was supported by a postdoctoral contract from RETICS-RTA. Jesús A García-Sevilla is a member of the Institut d’Estudis Catalans (Barcelona, Catalonia, Spain).</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article.</p>
<p>The study was supported in part by grants SAF2008-01311 and SAF2011-29918 from the Ministerio de Ciencia e Innovación (MICINN), Ministerio de Economía y Competitividad (MINECO), and Fondo Europeo de Desarrollo Regional (FEDER), Spain. The research was also funded by Redes Temáticas de Investigación Cooperativa en Salud-Red de Trastornos Adictivos (RETICS-RTA, RD06/0001/0003), Instituto de Salud Carlos III (MICINN/MINECO/FEDER, Madrid), Spain.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>The authors declare that there are no conflict of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alemany</surname><given-names>R</given-names></name>
<name><surname>Olmos</surname><given-names>G</given-names></name>
<name><surname>Escribá</surname><given-names>PV</given-names></name>
<etal/>
</person-group>. (<year>1995</year>) <article-title>LSL 60101, a selective ligand for imidazoline I<sub>2</sub> receptors, on glial fibrillary acidic protein concentration</article-title>. <source>Eur J Pharmacol</source> <volume>280</volume>: <fpage>205</fpage>–<lpage>210</lpage>.</citation>
</ref>
<ref id="bibr2-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alemany</surname><given-names>R</given-names></name>
<name><surname>Olmos</surname><given-names>G</given-names></name>
<name><surname>García-Sevilla</surname><given-names>JA</given-names></name>
</person-group> (<year>1997</year>) <article-title>Labelling of I<sub>2B</sub>-imidazoline receptors by [<sup>3</sup>H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) in rat brain and liver: characterization, regulation and relation to monoamine oxidase enzymes</article-title>. <source>Naunyn Schmiedeberg’s Arch Pharmacol</source> <volume>356</volume>: <fpage>39</fpage>–<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr3-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Álvaro-Bartolomé</surname><given-names>M</given-names></name>
<name><surname>Esteban</surname><given-names>S</given-names></name>
<name><surname>García-Gutiérrez</surname><given-names>MS</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Regulation of Fas receptor/Fas-associated protein with death domain apoptotic complex and associated signalling systems by cannabinoid receptors in the mouse brain</article-title>. <source>Br J Pharmacol</source> <volume>160</volume>: <fpage>643</fpage>–<lpage>656</lpage>.</citation>
</ref>
<ref id="bibr4-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Álvaro-Bartolomé</surname><given-names>M</given-names></name>
<name><surname>La Harpe</surname><given-names>R</given-names></name>
<name><surname>Callado</surname><given-names>LF</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Molecular adaptations of apoptotic pathways and signaling partners in the cerebral cortex of human cocaine addicts and cocaine-treated rats</article-title>. <source>Neuroscience</source> <volume>196</volume>: <fpage>1</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr5-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>NJ</given-names></name>
<name><surname>Lupo</surname><given-names>PA</given-names></name>
<name><surname>Nutt</surname><given-names>DJ</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Characterisation of imidazoline I<sub>2</sub> binding sites in pig brain</article-title>. <source>Eur J Pharmacol</source> <volume>519</volume>: <fpage>68</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr6-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boronat</surname><given-names>MA</given-names></name>
<name><surname>Olmos</surname><given-names>G</given-names></name>
<name><surname>García-Sevilla</surname><given-names>JA</given-names></name>
</person-group> (<year>1998</year>) <article-title>Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other I<sub>2</sub>-imidazoline ligands</article-title>. <source>Br J Pharmacol</source> <volume>125</volume>: <fpage>175</fpage>–<lpage>185</lpage>.</citation>
</ref>
<ref id="bibr7-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boronat</surname><given-names>MA</given-names></name>
<name><surname>García-Fuster</surname><given-names>MJ</given-names></name>
<name><surname>García-Sevilla</surname><given-names>JA</given-names></name>
</person-group> (<year>2001</year>) <article-title>Chronic morphine induces up-regulation of the pro-apoptotic Fas receptor and down-regulation of the anti-apoptotic Bcl-2 oncoprotein in rat brain</article-title>. <source>Br J Pharmacol</source> <volume>134</volume>: <fpage>1263</fpage>–<lpage>1270</lpage>.</citation>
</ref>
<ref id="bibr8-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Casanovas</surname><given-names>A</given-names></name>
<name><surname>Olmos</surname><given-names>G</given-names></name>
<name><surname>Ribera</surname><given-names>J</given-names></name>
<etal/>
</person-group>. (<year>2000</year>) <article-title>Induction of reactive astrocytosis and prevention of motoneuron cell death by the I<sub>2</sub>-imidazoline receptor ligand LSL60101</article-title>. <source>Br J Pharmacol</source> <volume>130</volume>: <fpage>1767</fpage>–<lpage>1776</lpage>.</citation>
</ref>
<ref id="bibr9-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chaitanya</surname><given-names>GV</given-names></name>
<name><surname>Alexander</surname><given-names>JS</given-names></name>
<name><surname>Babu</surname><given-names>PP</given-names></name>
</person-group> (<year>2010</year>) <article-title>PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration</article-title>. <source>Cell Commun Signal</source> <volume>8</volume>: <fpage>31</fpage>. DOI: <pub-id pub-id-type="doi">10.1186/1478-811X-8-31</pub-id>.</citation>
</ref>
<ref id="bibr10-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Choi</surname><given-names>SH</given-names></name>
<name><surname>Choi</surname><given-names>DH</given-names></name>
<name><surname>Lee</surname><given-names>JJ</given-names></name>
<etal/>
</person-group>. (<year>2002</year>) <article-title>Imidazoline drugs stabilize lysosomes and inhibit oxidative cytotoxicity in astrocytes</article-title>. <source>Free Rad. Biol Med</source> <volume>32</volume>: <fpage>394</fpage>–<lpage>405</lpage>.</citation>
</ref>
<ref id="bibr11-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dhanasekaran</surname><given-names>DN</given-names></name>
<name><surname>Reddy</surname><given-names>EP</given-names></name>
</person-group> (<year>2008</year>) <article-title>JNK signaling in apoptosis</article-title>. <source>Oncogene</source> <volume>27</volume>: <fpage>6245</fpage>–<lpage>6251</lpage>.</citation>
</ref>
<ref id="bibr12-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Díaz</surname><given-names>A</given-names></name>
<name><surname>Mayet</surname><given-names>S</given-names></name>
<name><surname>Dickeson</surname><given-names>AH</given-names></name>
</person-group> (<year>1997</year>) <article-title>BU-224 produces spinal antinociception as an agonist at imidazoline I<sub>2</sub> receptors</article-title>. <source>Eur J Pharmacol</source> <volume>333</volume>: <fpage>9</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr13-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dontenwill</surname><given-names>M</given-names></name>
<name><surname>Piletz</surname><given-names>JE</given-names></name>
<name><surname>Chen</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>IRAS is an anti-apoptotic protein</article-title>. <source>Ann NY Acad Sci</source> <volume>1009</volume>: <fpage>400</fpage>–<lpage>412</lpage>.</citation>
</ref>
<ref id="bibr14-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dupuy</surname><given-names>L</given-names></name>
<name><surname>Urosevic</surname><given-names>D</given-names></name>
<name><surname>Greney</surname><given-names>H</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>I<sub>1</sub> imidazoline receptor-mediated effects on apoptotic processes in PC12 cells</article-title>. <source>Cell Death Diff</source> <volume>11</volume>: <fpage>1049</fpage>–<lpage>1052</lpage>.</citation>
</ref>
<ref id="bibr15-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Edwards</surname><given-names>L</given-names></name>
<name><surname>Fishman</surname><given-names>D</given-names></name>
<name><surname>Horowitz</surname><given-names>P</given-names></name>
<etal/>
</person-group>. (<year>2001</year>) <article-title>The imidazoline-1 receptor in PC12 pheochromocytoma cells activates protein kinase C, extracellular signal-regulated kinsase (ERK) and c-jun N-terminal kinsase (JNK)</article-title>. <source>J Neurochem</source> <volume>79</volume>: <fpage>931</fpage>–<lpage>940</lpage>.</citation>
</ref>
<ref id="bibr16-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eglen</surname><given-names>RM</given-names></name>
<name><surname>Hudson</surname><given-names>AL</given-names></name>
<name><surname>Kendall</surname><given-names>DA</given-names></name>
<etal/>
</person-group>. (<year>1998</year>) <article-title>‘Seeing through a glass darkly’: casting light on imidazoline ‘I’ sites</article-title>. <source>Trends Pharmacol Sci</source> <volume>19</volume>: <fpage>381</fpage>–<lpage>390</lpage>.</citation>
</ref>
<ref id="bibr17-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Escribá</surname><given-names>PV</given-names></name>
<name><surname>Ozaita</surname><given-names>A</given-names></name>
<name><surname>Miralles</surname><given-names>A</given-names></name>
<etal/>
</person-group>. (<year>1995</year>) <article-title>Molecular characterization and isolation of a 45-kilodalton imidazoline receptor protein from the rat brain</article-title>. <source>Brain Res Mol Brain Res</source> <volume>32</volume>: <fpage>187</fpage>–<lpage>196</lpage>.</citation>
</ref>
<ref id="bibr18-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Escribá</surname><given-names>PV</given-names></name>
<name><surname>Ozaita</surname><given-names>A</given-names></name>
<name><surname>García-Sevilla</surname><given-names>JA</given-names></name>
</person-group> (<year>1999</year>) <article-title>Pharmacologic characterization of imidazoline receptor proteins identified by immunologic techniques and other methods</article-title>. <source>Ann NY Acad Sci</source> <volume>881</volume>: <fpage>8</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr19-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferrari</surname><given-names>F</given-names></name>
<name><surname>Fiorentino</surname><given-names>S</given-names></name>
<name><surname>Mennuni</surname><given-names>L</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain</article-title>. <source>J Pain Res</source> <volume>4</volume>: <fpage>111</fpage>–<lpage>125</lpage>.</citation>
</ref>
<ref id="bibr20-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Finn</surname><given-names>DP</given-names></name>
<name><surname>Martí</surname><given-names>O</given-names></name>
<name><surname>Harbuz</surname><given-names>MS</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>Behavioral, neuroendocrine and neurochemical effects of the imidazoline I<sub>2</sub> receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test</article-title>. <source>Psychopharmacology (Berl.)</source> <volume>167</volume>: <fpage>195</fpage>–<lpage>202</lpage>.</citation>
</ref>
<ref id="bibr21-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Galluzzi</surname><given-names>L</given-names></name>
<name><surname>Blomgren</surname><given-names>K</given-names></name>
<name><surname>Kroemer</surname><given-names>G</given-names></name>
</person-group> (<year>2009</year>) <article-title>Mitochondrial membrane permeabilization in neuronal injury</article-title>. <source>Nature Rev Neurosci</source> <volume>10</volume>: <fpage>481</fpage>–<lpage>494</lpage>.</citation>
</ref>
<ref id="bibr22-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>García-Fuster</surname><given-names>MJ</given-names></name>
<name><surname>Ferrer-Alcón</surname><given-names>M</given-names></name>
<name><surname>Miralles</surname><given-names>A</given-names></name>
<etal/>
</person-group>. (<year>2003</year>) <article-title>Modulation of Fas receptor proteins and dynamin during opiate addiction and induction of opiate withdrawal in rat brain</article-title>. <source>Naunyn-Schmiedeberg’s Arch Pharmacol</source> <volume>368</volume>: <fpage>421</fpage>–<lpage>431</lpage>.</citation>
</ref>
<ref id="bibr23-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>García-Fuster</surname><given-names>MJ</given-names></name>
<name><surname>Miralles</surname><given-names>A</given-names></name>
<name><surname>García-Sevilla</surname><given-names>JA</given-names></name>
</person-group> (<year>2007</year>) <article-title>Effects of opiate drugs on Fas-associated protein with death domain (FADD) and effector caspases in the rat brain: regulation by the ERK 1/2 MAP kinase pathway</article-title>. <source>Neuropsychopharmacology</source> <volume>32</volume>: <fpage>399</fpage>–<lpage>411</lpage>.</citation>
</ref>
<ref id="bibr24-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>García-Fuster</surname><given-names>MJ</given-names></name>
<name><surname>Ramos-Miguel</surname><given-names>A</given-names></name>
<name><surname>Miralles</surname><given-names>A</given-names></name>
<etal/>
</person-group>. (<year>2008a</year>) <article-title>Opioid receptor agonists enhance the phosphorylation state of Fas-associated death domain (FADD) protein in the rat brain: functional interactions with casein kinase Iα, Gαi proteins, and ERK 1/2 signaling</article-title>. <source>Neuropharmacology</source> <volume>55</volume>: <fpage>886</fpage>–<lpage>899</lpage>.</citation>
</ref>
<ref id="bibr25-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>García-Fuster</surname><given-names>MJ</given-names></name>
<name><surname>Ramos-Miguel</surname><given-names>A</given-names></name>
<name><surname>Rivero</surname><given-names>G</given-names></name>
<etal/>
</person-group>. (<year>2008b</year>) <article-title>Regulation of the extrinsic and intrinsic apoptotic pathways in the prefrontal cortex of short- and long-term human opiate abusers</article-title>. <source>Neuroscience</source> <volume>157</volume>: <fpage>105</fpage>–<lpage>119</lpage>.</citation>
</ref>
<ref id="bibr26-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>García-Fuster</surname><given-names>MJ</given-names></name>
<name><surname>Clinton</surname><given-names>SM</given-names></name>
<name><surname>Watson</surname><given-names>SJ</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Effect of cocaine on Fas-associated protein with death domain in the rat brain: Individual differences in a model of differential vulnerability to drug abuse</article-title>. <source>Neuropsychopharmacology</source> <volume>34</volume>: <fpage>1123</fpage>–<lpage>1134</lpage>.</citation>
</ref>
<ref id="bibr27-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>García-Sevilla</surname><given-names>JA</given-names></name>
<name><surname>Meana</surname><given-names>JJ</given-names></name>
<name><surname>Barturen</surname><given-names>F</given-names></name>
<etal/>
</person-group>. (<year>1993</year>) <article-title>New 2-benzofuranyl-imidazole derivatives with imidazoline receptor affinity, used as appetite stimulants or anti-anorexics</article-title>. <source>UK patent GB2262739-A</source>. Derwent primary accession number: <fpage>1993</fpage>-<lpage>207864</lpage>.</citation>
</ref>
<ref id="bibr28-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>García-Sevilla</surname><given-names>JA</given-names></name>
<name><surname>Escribá</surname><given-names>PV</given-names></name>
<name><surname>Guimón</surname><given-names>J</given-names></name>
</person-group> (<year>1999</year>) <article-title>Imidazoline receptors and human brain disorders</article-title>. <source>Ann NY Acad Sci</source> <volume>21</volume>: <fpage>392</fpage>–<lpage>409</lpage>.</citation>
</ref>
<ref id="bibr29-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>García-Vallejo</surname><given-names>P</given-names></name>
<name><surname>Barturen</surname><given-names>F</given-names></name>
<name><surname>García-Sevilla</surname><given-names>JA</given-names></name>
</person-group> (<year>1994</year>) <article-title>Modulation by central postsynaptic α<sub>2</sub>-adrenoceptors of the jaw-opening reflex induced by orofacial stimulation in rats</article-title>. <source>Br J Pharmacol</source> <volume>111</volume>: <fpage>1140</fpage>–<lpage>1146</lpage>.</citation>
</ref>
<ref id="bibr30-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gentili</surname><given-names>F</given-names></name>
<name><surname>Cardinaletti</surname><given-names>C.</given-names></name>
<name><surname>Carrieri</surname><given-names>A</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Involvement of I<sub>2</sub>-imidazoline binding sites in positive and negative morphine analgesia modulatory effects</article-title>. <source>Eur J Pharmacol</source> <volume>553</volume>: <fpage>73</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr31-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Greney</surname><given-names>H</given-names></name>
<name><surname>Ronde</surname><given-names>P</given-names></name>
<name><surname>Magnier</surname><given-names>C</given-names></name>
<etal/>
</person-group>. (<year>2000</year>) <article-title>Coupling of I<sub>1</sub> imidazoline receptors to the cAMP pathway: studies with a highly selective ligand, benazoline</article-title>. <source>Mol Pharmacol</source> <volume>57</volume>: <fpage>1142</fpage>–<lpage>1151</lpage>.</citation>
</ref>
<ref id="bibr32-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Han</surname><given-names>Z</given-names></name>
<name><surname>Xiao</surname><given-names>MJ</given-names></name>
<name><surname>Shao</surname><given-names>B</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Attenuation of ischemia-induced rat brain injury by 2-(-2-benzofuranyl)-2-imidazoline, a high selectivity ligand for imidazoline I-2 receptors</article-title>. <source>Neurol Res</source> <volume>31</volume>: <fpage>390</fpage>–<lpage>395</lpage>.</citation>
</ref>
<ref id="bibr33-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Han</surname><given-names>Z</given-names></name>
<name><surname>Zhang</surname><given-names>H-X</given-names></name>
<name><surname>Tian</surname><given-names>J-S</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>2-(2-benzofuranyl)-2-imidazoline induces Bcl-2 expression and provides neuroprotection against transient cerebral ischemia in rats</article-title>. <source>Brain Res</source> <volume>1361</volume>: <fpage>86</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr34-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Head</surname><given-names>GA</given-names></name>
<name><surname>Mayorov</surname><given-names>DN</given-names></name>
</person-group> (<year>2006</year>) <article-title>Imidazoline receptors, novel agents and therapeutic potential</article-title>. <source>Cardiovasc Hematol Agents Med Chem</source> <volume>4</volume>: <fpage>7</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr35-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hudson</surname><given-names>AL</given-names></name>
<name><surname>Chapleo</surname><given-names>CB</given-names></name>
<name><surname>Lewis</surname><given-names>JW</given-names></name>
<etal/>
</person-group>. (<year>1997</year>) <article-title>Identification of ligands selective for central I<sub>2</sub>-imidazoline binding sites</article-title>. <source>Neurochem Int</source> <volume>30</volume>: <fpage>47</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr36-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hudson</surname><given-names>AL</given-names></name>
<name><surname>Gough</surname><given-names>RE</given-names></name>
<name><surname>Tyacke</surname><given-names>R</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>Novel selective compounds for the investigation of imidazoline receptors</article-title>. <source>Ann NY Acad Sci</source> <volume>881</volume>: <fpage>81</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr37-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>S</given-names></name>
<name><surname>Zheng</surname><given-names>R-Y</given-names></name>
<name><surname>Zeng</surname><given-names>J-Q</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Reversible inhibition of intracellular calcium influx through NMDA receptors by imidazoline I<sub>2</sub> receptor antagonists</article-title>. <source>Eur J Pharmacol</source> <volume>629</volume>: <fpage>12</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr38-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kawamura</surname><given-names>K</given-names></name>
<name><surname>Maeda</surname><given-names>J</given-names></name>
<name><surname>Hatori</surname><given-names>A</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>In vivo and in vitro imaging of I<sub>2</sub> imidazoline receptors in the monkey brain</article-title>. <source>Synapse</source> <volume>65</volume>: <fpage>452</fpage>–<lpage>455</lpage>.</citation>
</ref>
<ref id="bibr39-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kimura</surname><given-names>A</given-names></name>
<name><surname>Tyacke</surname><given-names>RJ</given-names></name>
<name><surname>Robinson</surname><given-names>JJ</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Identification of an imidazoline binding protein: creatine kinase and an imidazoline-2 binding site</article-title>. <source>Brain Res</source> <volume>1279</volume>: <fpage>21</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr40-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Korsmeyer</surname><given-names>SJ</given-names></name>
<name><surname>Shutter</surname><given-names>JR</given-names></name>
<name><surname>Veis</surname><given-names>DJ</given-names></name>
<etal/>
</person-group>. (<year>1993</year>) <article-title>Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death</article-title>. <source>Semin Cancer Biol</source> <volume>4</volume>: <fpage>327</fpage>–<lpage>332</lpage>.</citation>
</ref>
<ref id="bibr41-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>S</given-names></name>
</person-group> (<year>2007</year>) <article-title>Caspase function in programmed cell death</article-title>. <source>Cell Death Differ</source> <volume>14</volume>: <fpage>32</fpage>–<lpage>43</lpage>.</citation>
</ref>
<ref id="bibr42-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>J-X</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
</person-group> (<year>2011</year>) <article-title>Imidazoline I<sub>2</sub> receptors: target for new analgesics?</article-title> <source>Eur J Pharmacol</source> <volume>658</volume>: <fpage>49</fpage>–<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr43-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>J-X</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Winter</surname><given-names>JC</given-names></name>
</person-group> (<year>2011</year>) <article-title>Morphine-induced antinociception in the rat: supra-additive interactions with imidazoline I<sub>2</sub> receptor ligands</article-title>. <source>Eur J Pharmacol</source> <volume>669</volume>: <fpage>59</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr44-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lione</surname><given-names>LA</given-names></name>
<name><surname>Nutt</surname><given-names>DJ</given-names></name>
<name><surname>Hudson</surname><given-names>AL</given-names></name>
</person-group> (<year>1998</year>) <article-title>Characterisation and localisation of [<sup>3</sup>H]2-(2-benzofuranyl)-2-imidazoline binding in rat brain: a selective ligand for imidazoline I<sub>2</sub> receptors</article-title>. <source>Eur J Pharmacol</source> <volume>353</volume>: <fpage>123</fpage>–<lpage>135</lpage>.</citation>
</ref>
<ref id="bibr45-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lossi</surname><given-names>L</given-names></name>
<name><surname>Merighi</surname><given-names>A</given-names></name>
</person-group> (<year>2003</year>) <article-title>In vivo cellular and molecular mechanisms of neuronal apoptosis in the mammalian CNS</article-title>. <source>Progr Neurobiol</source> <volume>69</volume>: <fpage>287</fpage>–<lpage>312</lpage>.</citation>
</ref>
<ref id="bibr46-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lui</surname><given-names>T-N</given-names></name>
<name><surname>Tsao</surname><given-names>C-W</given-names></name>
<name><surname>Huang</surname><given-names>S-Y</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Activation of imidazoline I<sub>2B</sub> receptors is linked with AMP kinase pathway to increase glucose uptake in cultured C<sub>2</sub>C<sub>12</sub> cells</article-title>. <source>Neurosci Lett</source> <volume>474</volume>: <fpage>144</fpage>–<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr47-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meana</surname><given-names>JJ</given-names></name>
<name><surname>Barturen</surname><given-names>F</given-names></name>
<name><surname>García-Sevilla</surname><given-names>JA</given-names></name>
</person-group> (<year>1989</year>) <article-title>Characterization and regional distribution of α<sub>2</sub>-adrenoceptors in postmortem human brain using the full agonist [<sup>3</sup>H]UK14304</article-title>. <source>J Neurochem</source> <volume>52</volume>: <fpage>1210</fpage>–<lpage>1217</lpage>.</citation>
</ref>
<ref id="bibr48-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Menargues</surname><given-names>A</given-names></name>
<name><surname>Obach</surname><given-names>R</given-names></name>
<name><surname>García-Sevilla</surname><given-names>JA</given-names></name>
</person-group> (<year>1990</year>) <article-title>Modulation by antidepressant drugs of CNS postsynaptic α<sub>2</sub>-adrenoceptors mediating mydriasis in the rat</article-title>. <source>Naunyn-Schmiedeberg’s Arch Pharmacol</source> <volume>341</volume>: <fpage>101</fpage>–<lpage>107</lpage>.</citation>
</ref>
<ref id="bibr49-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Milhaud</surname><given-names>D</given-names></name>
<name><surname>Fagni</surname><given-names>L</given-names></name>
<name><surname>Bockaert</surname><given-names>J</given-names></name>
<etal/>
</person-group>. (<year>2000</year>) <article-title>Imidazoline-induced neuroprotective effects result from blockade of NMDA receptor channels in neuronal cultures</article-title>. <source>Neuropharmacology</source> <volume>39</volume>: <fpage>2244</fpage>–<lpage>2254</lpage>.</citation>
</ref>
<ref id="bibr50-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miralles</surname><given-names>A</given-names></name>
<name><surname>Olmos</surname><given-names>G</given-names></name>
<name><surname>Sastre</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>1993</year>) <article-title>Discrimination and pharmacological characterization of I<sub>2</sub>-imidazoline sites with [<sup>3</sup>H]idazoxan and alpha-2 adrenoceptors with [<sup>3</sup>H]RX821002 (2-methoxy idazoxan) in the human and rat brains</article-title>. <source>J Pharmacol Exp Ther</source> <volume>264</volume>: <fpage>1187</fpage>–<lpage>1197</lpage>.</citation>
</ref>
<ref id="bibr51-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Molderings</surname><given-names>GJ</given-names></name>
<name><surname>Bönisch</surname><given-names>H</given-names></name>
<name><surname>Bruss</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>S1P-receptors in PC12 and transfected HEK293 cells: molecular targets of hypotensive imidazoline I(1) receptor ligands</article-title>. <source>Neurochem Int</source> <volume>51</volume>: <fpage>476</fpage>–<lpage>485</lpage>.</citation>
</ref>
<ref id="bibr52-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morgan</surname><given-names>NG</given-names></name>
<name><surname>Chan</surname><given-names>SL</given-names></name>
</person-group> (<year>2001</year>) <article-title>Imidazoline binding sites in the endocrine pancreas: can they fulfil their potential as targets for the development of new insulin secretagogues?</article-title> <source>Curr Pharm Des</source> <volume>7</volume>: <fpage>1413</fpage>–<lpage>1431</lpage>.</citation>
</ref>
<ref id="bibr53-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nutt</surname><given-names>DJ</given-names></name>
<name><surname>French</surname><given-names>N</given-names></name>
<name><surname>Handley</surname><given-names>S</given-names></name>
<etal/>
</person-group>. (<year>1995</year>) <article-title>Functional studies of specific imidazoline-2 receptor ligands</article-title>. <source>Ann NY Acad Sci</source> <volume>763</volume>: <fpage>125</fpage>–<lpage>139</lpage>.</citation>
</ref>
<ref id="bibr54-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Olmos</surname><given-names>G</given-names></name>
<name><surname>Miralles</surname><given-names>A</given-names></name>
<name><surname>Barturen</surname><given-names>F</given-names></name>
<etal/>
</person-group>. (<year>1992</year>) <article-title>Characterization of brain imidazoline receptors in normotensive and hypertensive rats: differential regulation by chronic imidazoline drug treatment</article-title>. <source>J Pharmacol Exp Ther</source> <volume>260</volume>: <fpage>1000</fpage>–<lpage>1007</lpage>.</citation>
</ref>
<ref id="bibr55-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Olmos</surname><given-names>G</given-names></name>
<name><surname>Alemany</surname><given-names>R</given-names></name>
<name><surname>Escribá</surname><given-names>PV</given-names></name>
<etal/>
</person-group>. (<year>1994</year>) <article-title>The effects of chronic imidazoline drug treatment on glial fibrillary acidic protein concentrations in rat brain</article-title>. <source>Br J Pharmacol</source> <volume>111</volume>: <fpage>997</fpage>–<lpage>1002</lpage>.</citation>
</ref>
<ref id="bibr56-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Olmos</surname><given-names>G</given-names></name>
<name><surname>Ribera</surname><given-names>J</given-names></name>
<name><surname>García-Sevilla</surname><given-names>JA</given-names></name>
</person-group> (<year>1996</year>) <article-title>Imidazoli(di)ne compounds interact with the phencyclidine site of NMDA receptors in the rat brain</article-title>. <source>Eur J Pharmacol</source> <volume>310</volume>: <fpage>273</fpage>–<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr57-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Olmos</surname><given-names>G</given-names></name>
<name><surname>DeGregorio-Rocasolano</surname><given-names>N</given-names></name>
<name><surname>Regalado</surname><given-names>PM</given-names></name>
<etal/>
</person-group>. (<year>1999</year>) <article-title>Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor</article-title>. <source>Br J Pharmacol</source> <volume>127</volume>: <fpage>1317</fpage>–<lpage>1326</lpage>.</citation>
</ref>
<ref id="bibr58-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ozaita</surname><given-names>A</given-names></name>
<name><surname>Olmos</surname><given-names>G</given-names></name>
<name><surname>Boronat</surname><given-names>MA</given-names></name>
<etal/>
</person-group>. (<year>1997</year>) <article-title>Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I<sub>2</sub>-imidazoline receptors in rat liver</article-title>. <source>Br J Pharmacol</source> <volume>121</volume>: <fpage>901</fpage>–<lpage>912</lpage>.</citation>
</ref>
<ref id="bibr59-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pigini</surname><given-names>M</given-names></name>
<name><surname>Bousquet</surname><given-names>P</given-names></name>
<name><surname>Carotti</surname><given-names>A</given-names></name>
<etal/>
</person-group>. (<year>1997</year>) <article-title>Imidazoline receptors: qualitative structure-activity relationships and discovery of tracizoline and benazoline. Two ligands with high affinity and unprecedented selectivity</article-title>. <source>Bioorg Med Chem</source> <volume>5</volume>: <fpage>833</fpage>–<lpage>841</lpage>.</citation>
</ref>
<ref id="bibr60-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Piletz</surname><given-names>JE</given-names></name>
<name><surname>Ivanov</surname><given-names>TR</given-names></name>
<name><surname>Sharp</surname><given-names>JD</given-names></name>
<etal/>
</person-group>. (<year>2000</year>) <article-title>Imidazoline receptor antisera-selected (IRAS) cDNA: cloning and characterization</article-title>. <source>DNA Cell Biol</source> <volume>19</volume>: <fpage>319</fpage>–<lpage>329</lpage>.</citation>
</ref>
<ref id="bibr61-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Qiu</surname><given-names>W-W</given-names></name>
<name><surname>Zheng</surname><given-names>R-Y</given-names></name>
</person-group> (<year>2006</year>) <article-title>Neuroprotective effects of receptor imidazoline 2 and its endogenous ligand agmatine</article-title>. <source>Neurosci Bull</source> <volume>22</volume>: <fpage>187</fpage>–<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr62-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Raddatz</surname><given-names>R</given-names></name>
<name><surname>Parini</surname><given-names>A</given-names></name>
<name><surname>Lanier</surname><given-names>SM</given-names></name>
</person-group> (<year>1995</year>) <article-title>Imidazoline/guanidium binding domains on monoamine oxidases</article-title>. <source>J Biol Chem</source> <volume>270</volume>: <fpage>27961</fpage>–<lpage>27968</lpage>.</citation>
</ref>
<ref id="bibr63-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Raddatz</surname><given-names>R</given-names></name>
<name><surname>Parini</surname><given-names>A</given-names></name>
<name><surname>Lanier</surname><given-names>SM</given-names></name>
</person-group> (<year>1997</year>) <article-title>Localization of the imidazolinbe binding domain on monoamine oxidase B</article-title>. <source>Mol Pharmacol</source> <volume>52</volume>: <fpage>549</fpage>–<lpage>553</lpage>.</citation>
</ref>
<ref id="bibr64-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ramos-Miguel</surname><given-names>A</given-names></name>
<name><surname>Miralles</surname><given-names>A</given-names></name>
<name><surname>García-Sevilla</surname><given-names>JA</given-names></name>
</person-group> (<year>2011</year>) <article-title>Correlation of rat cortical Fas-associated death domain (FADD) protein phosphorylation with the severity of spontaneous morphine abstinence syndrome: role of α<sub>2</sub>-adrenoceptors and extracellular signal-regulated kinases</article-title>. <source>J Psychopharmacol</source> <volume>25</volume>: <fpage>1690</fpage>–<lpage>1701</lpage>.</citation>
</ref>
<ref id="bibr65-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Regunathan</surname><given-names>S</given-names></name>
<name><surname>Feinstein</surname><given-names>DL</given-names></name>
<name><surname>Reis</surname><given-names>DJ</given-names></name>
</person-group> (<year>1993</year>) <article-title>Expression of non-adrenergic imidazoline sites in rat cerebral cortical astrocytes</article-title>. <source>J Neurosci Res</source> <volume>34</volume>: <fpage>681</fpage>–<lpage>688</lpage>.</citation>
</ref>
<ref id="bibr66-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Regunathan</surname><given-names>S</given-names></name>
<name><surname>Reis</surname><given-names>DJ</given-names></name>
</person-group> (<year>1996</year>) <article-title>Imidazoline receptors and their endogenous ligands</article-title>. <source>Annu Rev Pharmacol Toxicol</source> <volume>36</volume>: <fpage>511</fpage>–<lpage>544</lpage>.</citation>
</ref>
<ref id="bibr67-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruggiero</surname><given-names>DA</given-names></name>
<name><surname>Reguhathan</surname><given-names>S</given-names></name>
<name><surname>Wang</surname><given-names>H</given-names></name>
<etal/>
</person-group>. (<year>1998</year>) <article-title>Immunocytochemical localization of an imidazoline receptor protein in the central nervous system</article-title>. <source>Brain Res</source> <volume>780</volume>: <fpage>270</fpage>–<lpage>293</lpage>.</citation>
</ref>
<ref id="bibr68-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sánchez-Blázquez</surname><given-names>P</given-names></name>
<name><surname>Boronat</surname><given-names>MA</given-names></name>
<name><surname>Olmos</surname><given-names>G</given-names></name>
<etal/>
</person-group>. (<year>2000</year>) <article-title>Activation of I<sub>2</sub>-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors</article-title>. <source>Br J Pharmacol</source> <volume>130</volume>: <fpage>146</fpage>–<lpage>152</lpage>.</citation>
</ref>
<ref id="bibr69-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sastre-Coll</surname><given-names>A</given-names></name>
<name><surname>Esteban</surname><given-names>S</given-names></name>
<name><surname>Miralles</surname><given-names>A</given-names></name>
<etal/>
</person-group>. (<year>2001</year>) <article-title>The imidazoline receptor ligand 2-(2-benzofuranyl)-2-imidazoline is a dopamine-releasing agent in the rat stiatum in vivo</article-title>. <source>Neurosci Lett</source> <volume>301</volume>: <fpage>29</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr70-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Separovic</surname><given-names>D</given-names></name>
<name><surname>Kester</surname><given-names>M</given-names></name>
<name><surname>Ernsberger</surname><given-names>P</given-names></name>
</person-group> (<year>1996</year>) <article-title>Coupling of I<sub>1</sub>-imidazoline receptors to diacylglyceride accumulation in PC12 rat pheochromocytoma cells</article-title>. <source>Mol Pharmacol</source> <volume>49</volume>: <fpage>668</fpage>–<lpage>675</lpage>.</citation>
</ref>
<ref id="bibr71-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>KL</given-names></name>
<name><surname>Jessop</surname><given-names>DS</given-names></name>
<name><surname>Finn</surname><given-names>DP</given-names></name>
</person-group> (<year>2009</year>) <article-title>Modulation of stress by imidazoline binding sites: implications for psychiatric disorders</article-title>. <source>Stress</source> <volume>12</volume>: <fpage>97</fpage>–<lpage>114</lpage>.</citation>
</ref>
<ref id="bibr72-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stabile</surname><given-names>AM</given-names></name>
<name><surname>Aceros</surname><given-names>H</given-names></name>
<name><surname>Stockmeyer</surname><given-names>K</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Functional and molecular effects of imidazoline receptor activation in heart failure</article-title>. <source>Life Sci</source> <volume>88</volume>: <fpage>493</fpage>–<lpage>503</lpage>.</citation>
</ref>
<ref id="bibr73-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thorn</surname><given-names>DA</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Peng</surname><given-names>B-W</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Effects of imidazoline I2 receptor ligands on morphine- and tramadol-induced antinociception in rats</article-title>. <source>Eur J Pharmacol</source> <volume>670</volume>: <fpage>435</fpage>–<lpage>440</lpage>.</citation>
</ref>
<ref id="bibr74-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tonello</surname><given-names>R</given-names></name>
<name><surname>Villarinho</surname><given-names>JG</given-names></name>
<name><surname>da Silva Sant’anna</surname><given-names>G</given-names></name>
<etal/>
</person-group>. (<year>2012</year>) <article-title>The potential antidepressant-like effect of imidazoline I<sub>2</sub> ligand 2-BFI in mice</article-title>. <source>Prog Neuro-Psychopharmacol Biol Psychiatry</source> <volume>37</volume>: <fpage>15</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr75-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tourneur</surname><given-names>L</given-names></name>
<name><surname>Chiocchia</surname><given-names>G</given-names></name>
</person-group> (<year>2010</year>). <article-title>FADD: a regulator of life and death</article-title>. <source>Trends Immunol</source> <volume>31</volume>: <fpage>260</fpage>–<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr76-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Uzbay</surname><given-names>TI</given-names></name>
</person-group> (<year>2012</year>) <article-title>The pharmacological importance of agmatine in the brain</article-title>. <source>Neurosci Biobehav Rev</source> <volume>36</volume>: <fpage>502</fpage>–<lpage>519</lpage>.</citation>
</ref>
<ref id="bibr77-0269881112450785">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>P</given-names></name>
<name><surname>Wang</surname><given-names>ZW</given-names></name>
<name><surname>Lin</surname><given-names>FH</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>2-BFI attenuates experimental autoimmune encephalomyelitis-induced spinal cord injury with enhanced B-CK, CaATPase, but reduced calpain activity</article-title>. <source>Biochem Biophys Res Commun</source> <volume>406</volume>: <fpage>152</fpage>–<lpage>157</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>